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Summary 
 
 
Hormone Nuclear Receptors : Structure and Molecular Dynamics of 
Retinoic Acid Receptor (RAR) allosteric complexes 
 
The Retinoic Acid Receptor (RAR) belongs to the large family of nuclear receptors 
(NRs). Nuclear receptors are ligand dependent transcription activators: they mediate the 
effect of specific ligands by means of interacting with the general transcription 
machinery and modulating the expression of a specific subset of genes. 
RAR acts as a heterodimer with its functional partner, the retinoid X receptor (RXR) 
and exists in three main forms, the isotypes α, β, γ. RAR shares a common modular 
organization with prototypical NRs with a DNA binding (DBD) domain and a ligand 
binding domain (LBD). 
Nuclear receptors are phosphoproteins: RAR is phosphorylated at the LBD by the cyclic 
AMP dependent protein kinase PKA and subsequently at the N-terminal domain (AB 
domain) by the heterotrimeric complex CAK composed of Cdk7 kinase, Cyclin H, and 
MAT1 and belonging to the TFIIH general transcription factor. Phosphorylation at the 
ligand binding domain at position S369 for RARα and S371 for RARγ by PKA 
enhances the binding of Cyclin H to the receptor therefore facilitating the 
phosphorylation of the AB domain by CAK and activating the transcription of retinoic 
target genes. 
Our project aims at providing new structural insights to understand at atomic level how 
phosphorylation by PKA participates in nuclear receptors signalling. The crystal 
structures of 
hRARγ and hCycH have already been determined in our group. 
Now we aim at investigating the consequences of PKA phosphorylation on the structure 
of the RAR LDB. In this perspective we need to compare the high resolution crystal 
structures of the unphosphorylated RAR LBD with that of the phosphorylated receptor 
or with that of the S371E mutant in which the mutation is well known to mimic a 
phosphorylation event. We need as well to perform NMR studies on the 
unphosphorylated RAR LBD and on the phosphorylated receptor or the S371E mutant 
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in order to highlight differences in the structure dynamics due to the phosphorylation of 
the residue S371. 
 
The work that I performed during my thesis can be divided in three main sections: 
 
Section 1- Samples preparation 
 
A point mutation exchanging a serine for a glutamic acid was introduced respectively in 
position 369 and 371 of hRARα and hRARγ (LBD) in order to mimic a phosphorylation 
event. Starting from the corresponding expression vectors, small scale expression tests 
were performed to optimize the conditions for the expression of the nuclear receptors 
hRARα, hRARαS369E, hRARγ, hRARγS371E, hRXRα. Scaling up to large scale 
cultures did not require any modifications in the set up conditions. Nuclear receptor 
samples enriched with the NMR active isotope 15N were produced to perform 
subsequent NMR mobility experiments. A common purification protocol consisting in a 
metal affinity chromatography followed by a size exclusion chromatography was set up 
for the nuclear receptors.  
The full length hCycH was expressed to perform biophysical characterization 
experiments of the interaction between hCycH and hRARα. 
The catalytic domain of the cyclic AMP dependent protein kinase (c-PKA) was 
expressed and purified in order to perform in vitro phosphorylation essays onto RAR. 
The phosphorylation of hRARα onto the residue Ser 369 by PKA has been checked by 
immunoblotting and reconfirmed by LC mass spectrometry analysis.  
 
 
Section 2-  Crystal structure of hRARγS371E LBD 
 
 
The ligand binding domain of hRARαS369E was expressed and purified. The protein 
bound to the agonist ligand 9-cis retinoic acid was concentrated up to 6 mg/ml and 
crystallized in presence of a SRC1 co-activator peptide. Crystals diffracted on a 
synchrotron source up to 2.7 Ǻ but resulted highly mosaic. Several attempts to optimize 
the crystallization conditions resulted unfortunately not successful. The other protein 
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isotype hRARγS37l E (LBD) was expressed and purified with a yield of 7 mg of pure 
protein per 1 litre of culture. The protein was concentrated up to 6 mg/ml. The 
hRARγS371E bound to the ligand 9-cis retinoic acid (holo receptor) crystallized over 
night in presence of detergents. Optimized crystals were tested on a synchrotron source 
and a complete data set was collected at 1.7 Ǻ. Crystals belong to the tetragonal space 
group P4121 2 with one monomer per asymmetric unit. The structure was solved by 
molecular replacement using hRARγWT as a starting model. After refinement the 
reported values for Rfactor and Rfree were respectively of 19.4% and 23.4%. 
The human RARγS371E-holo-LBD adopts a classical anti-parallel alpha helical 
"sandwich" conformation firstly described for hRARγ. The electron density map 
showed the presence of the ligand buried into the ligand binding pocket and an extra 
electron density around position 371 confirmed the mutation of the serine residue into a 
glutamic acid. 
 
The hRARγS371E LBD and hRARγ LBD structures are isomorphous with an r.m.s. 
deviation of 0.47 Ǻ on the overall structure. Analysis of the r.m.s.d values obtained 
from the superposition of RARWT and RAR mutant carbon alphas of the backbone 
enlightened that two regions in RARγS371E display larger r.m.s.d values. Interestingly 
one of these two regions involves residues (340-343) which are located in the region of 
the receptor that is responsible for the recognition and binding of hCycH and previously 
shown to be essential for hCycH docking. The analysis of the structures of hRARγWT 
and the mutant hRARγS371E showed very similar overall orientation of the side chains. 
Remarkably a significant difference in the orientation of the side chains involves again 
the region of the receptor responsible for hCycH binding. More precisely this difference 
is located at the level of the residue ASP340. In hRARγS371E this residue, belonging to 
loop 8-9, forms a salt bridge with ARG387 belonging to helix H10. This salt bridge is 
not formed in the hRARγWT due to the orientation of the ARG387 which now points 
toward the solvent. Our results were confirmed by molecular dynamic simulations 
performed in collaboration with Dr. Annick Dejaegere’s group in Strasbourg. 
Simulations carried out onto hRARγS371E enlightened the presence of the salt bridge 
which is unmodified during in the dynamics.  
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The same simulations carried onto hRARγWT showed that the formation of the salt 
bridge between ARG387 and ASP340 is transient. 
 
Section 3- Dynamic studies of RARα wild type and RARαS369E (LBD) by Nuclear 
Magnetic resonance (NMR). 
 
X-ray crystallography and NMR spectroscopy are the two main techniques that can 
provide the structure of macromolecules at atomic resolution. Both techniques are well 
established and play already a key role in structural biology as a basis for a detailed 
understanding of molecular functions. X-ray crystallography requires single crystals 
whereas NMR measurements are carried out in solution under conditions that can be as 
close as possible to the physiological conditions. Furthermore, the analysis through 
NMR spectroscopy easily allows the characterization under several, different 
experimental conditions, such as different ionic strength and pH. NMR measurements 
not only provide structural data but can also supply information on the internal mobility 
of proteins on various time scales, on protein folding and on intra, as well as, 
intermolecular interactions. Protein mobility has an increasing relevance to our 
understanding of biological and chemical phenomena for the recognized importance of 
protein internal motions in biological processes. Macromolecular functions are often 
associated to energetic transition, which are intimately connected with structural 
changes and molecular flexibility. 
The measurement of l5N relaxation rates in isotopically enriched proteins is particularly 
useful for obtaining dynamic information. In l5N relaxation experiments, one creates 
non-equilibrium spin order and records how this relaxes back to equilibrium. At 
equilibrium, the l5N magnetization is aligned along the external field, and this alignment 
can be changed by radio frequency pulses. The magnetization will relax back to 
equilibrium along the direction of the magnetic filed with a longitudinal relaxation 
constant R1. The magnetization can also have a second component perpendicular to the 
external magnetic field. The relaxation constant for this spin component to return to 
equilibrium is called transverse relaxation constant R2. 
In order to highlight differences in the dynamics of wild type RAR and its mutant we 
performed 15N longitudinal and traverse relaxation rates measurements on both proteins 
at 500 MHz and 298K. We focused our attention on the α isotype of RAR for which the 
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most extensive biologic data are available. The large majority of the analyzed residues 
feature very similar rates except for 10 residues that in RARαS369E have higher 
longitudinal rates with respect to the wild type. To analyze in details the difference in 
mobility between RARα wild type and its mutant protein backbone assignment is 
needed. Due to RAR high molecular weight, protein assignment will require 
RARα samples enriched with 2H/13C/15N isotopes. 
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Nuclear Receptors 
 
Nuclear receptors (NRs) constitute a large class of structurally-related proteins that act 
as ligand inducible transcription factors. Nuclear receptors bind specific DNA 
regulatory elements (HREs) and are functionally active as monomers or homo-
heterodimers. Their distinctive feature is to bind small lipophilic molecules such as 
hormones, vitamins derivatives and metabolic intermediates that act as signalling 
ligands. Ligand binding to the receptor induces radical conformational changes that 
modulate the receptor transcriptional activity and therefore the expression of subsets of 
target genes. Nuclear receptors take active part into the “cross-talk” with other signal 
transduction pathways thus integrating intra and extra-cellular signals and modulating a 
multitude of genetic programs that regulate all stages of the life of multicellular 
organisms such as embryonic development, differentiation of cellular phenotypes, cell 
proliferation and apoptosis.  
Malfunctioning of the receptors leads to severe diseases such as cancer, diabetes and 
obesity5, 74, 100.  
 
 
1. The Nuclear Receptor family and its ligands 
 
Classical receptors were identified on the basis of their reported ability to transduce the 
signal of known hormones. Biochemical and structural studies revealed common 
structural features for these receptors and allowed a systematic screening of c-DNA 
libraries. This extensive research brought to the isolation of several c-DNA encoding for 
proteins that shared high sequence conservation with the nuclear receptors but for which 
the corresponding ligand was previously unknown. These new proteins were defined as 
“Orphan Receptors”. For long time a clear distinction was made between classical and 
orphan nuclear receptors. However the recent discovery of several ligands for orphan 
receptors and the presence of orphan receptors in all branches of NRs phylogenetic tree 
moderated the necessity for this discrimination. The history of the evolution of the NR 
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superfamily has been reconstituted on the basis of broad sequence analysis and led to 
nuclear receptors grouping in six subfamilies composed by the following members101, 
115
 : 
 
I.  The Thyroid hormone (TR), Vitamin D (VDR), Retinoic Acid (RAR), Peroxisome 
Proliferator-Activated (PPAR), Ecdysone (EcR) Receptors and numerous Orphan 
Receptors as ROR, Rev-erb. 
 
II.  The Retinoid X receptor (RXR), the Chicken Ovalbumin Upstream Promoter 
Transcription Factor (COUP-TF) and the Hepatocyte Nuclear Factor 4 (HNF4). 
 
III.   The Estrogen (ER), Mineralocorticoid (MR), Glucocorticoid (GR), Androgen (AR), 
Progesterone (PR), and the orphan Estrogen-Related Receptors (EER). 
 
IV.  The Nerve Growth Factor-Induced clone B (NGFIB) orphan receptor. 
 
V. The Steroidogenic Factor1 (SF1) and the Drosophila Fushi Tarazu Factor1 (FTZ-F1)  
 
VI. The Germ Cell Nuclear Factor (GCNF1) receptor 
 
This classification provided evidence for a correlation between the receptor position in 
the phylogenetic tree and their dimerization features, suggesting that most probably the 
common ancestral NR bound DNA as a homodimer and that the ability to 
heterodimerize was acquired when receptor classes I and IV differentiated. Instead no 
correlation can be found between chemically-related hormones and receptor position in 
the phylogenetic tree leading to the conclusion that the ability to bind a ligand was not 
inherited by a common ancestor but rather acquired independently at different stages of 
receptors evolution. The analysis of the phylogenetic tree suggests that nuclear receptors 
are found only in metazoans and that their evolution went through two “waves of 
duplication”: the first at the appearance of all metazoans originated the six subclasses 
weather the second, at the differentiation of anthropoids and vertebrates, originated 
different isotypes for a same family (i.e. RAR α, β, γ or ER α,β)70, 100, 101 
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Table.1- Some of the Nuclear Receptors with their cognate ligand 
 
 
 
NR Ligand  Chemical 
formula  
NR Ligand  Chemical 
formula  
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2. Modular Organization of NRs 
 
2.1 Overview 
 
All NRs share a common organization in functional domains, each encoding a specific 
function.  NRs contain up to six of such regions designated from A to F (Fig.1). 
The N-terminal regions A/B, commonly identified as the A/B domain, display the 
weakest evolutionary conservation amongst NRs and harbour one ligand-independent 
and constitutive active transcriptional activation function (AF-1). The DNA-binding 
domain (C domain) represents the most evolutionary conserved region in NRs and it 
notably contains a short motif responsible for the sequence specific DNA recognition. 
The D region does not display a high evolutionary conservation. It is classically thought 
to serve as a “hinge” region that reduces steric hindrance problems and allows the 
nuclear receptor to adopt different conformations. The E domain or ligand binding 
domain (LBD) is the hallmark of each nuclear receptor. This highly conserved domain 
bears the ligand binding pocket as well as the ligand-dependent transcription activation 
function (AF-2) and a large interaction surface which allows interactions with multiple 
partners such as homo and heterodimeric partners, corepressors and coactivators. Some 
receptors possess a C-terminal region called F domain with weak evolutionary 
conservation. The role of this region is still unknown. 
 
 
 
 
Fig.1- Structural organization of NRs in distinct domains. The evolutionary conserved 
regions C/E are indicated by the purple boxes while the yellow bar represents the divergent 
regions A/B, D, F. 
 
 
F A/B D 
AF-1 AF-2 
Ligand independent 
transactivation function DNA binding 
Hinge 
region 
Ligand dependent    
transactivation function 
AD C E AD 
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2.2 The A/B Domain – Ligand independent transactivation 
domain 
 
2.2.1 Structure 
 
The N-terminal A/B is the least conserved region among NRs. Isoforms of the same 
nuclear receptor, originated from the same gene by alternative splicing or different 
promoter usage, differ exclusively in their NH2-terminal region. This is the case, for 
example, for the thyroid hormone receptor (TR) isoforms TRβ1 and TRβ2 or for the 
RAR gene isoforms (α,β,γ). The A/B domain is also sensibly variable in length and it 
can range from 23 amino acids in vitamin D receptor, to 602 amino acids in the 
mineralocorticoid receptors181. Nuclear receptors contain at least two domains that 
possess the ability of activating transcription (AFs), a ligand-independent activation 
function (AF-1) generally localized in the N-terminal region and a ligand dependent 
activation function (AF-2) generally harboured in the ligand-binding domain5. The 
synergy between the AFs guarantees the full transcriptional efficiency of the nuclear 
receptor. Nevertheless it has been shown that the AF-1 function is able to activate 
transcription in a constitutive manner. Truncated estrogen (ER) or progesterone (PR) 
receptors containing the AF-1 function associated with the DNA binding domain 
efficiently stimulate transcription in a ligand independent fashion. The AF-1 
transactivation function exhibits cell type, DNA-binding domain and target gene 
promoter specificity15, 118. The origin of this strong dependence is still unclear but might 
be related to the cell specific mode of action or to the presence within the cell of 
specific AF-1 coactivators. 
To date no structure determination of the A/B nuclear receptor domain is available due 
to the lack of structural organization for this region. Magnetic resonance and circular 
dichroism studies demonstrated that the AF-1 region of glucocorticoid receptor (GR) 
and the N-terminal region of oestrogen receptor are disordered in solution. Proteolysis 
essays pointed out that progesterone receptor (PR) N-terminus is also poorly structured. 
Experiments performed in presence of α-helical stabilizing agents as trifluorethanol 
demonstrated that the AF-1 structure is incline to adopt a α-helical conformation. When 
residues involved in the putative α-helix are mutated in prolines the ability of AF-1 to 
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form α-helices in trifluoroethanol is remarkably reduced and concomitantly the 
transactivation activity of this domain decreases suggesting that the formation of α -
helices is important for AF-1 to mediated gene activation181. 
 
 
2.2.2 Coactivators mediated folding of the AF-1 domain 
 
Regulation of transcriptional activity by nuclear receptors requires a battery of 
coregulatory proteins often constituted by subunits of larger multiprotein complexes. 
Coregulators are divided into coactivators or corepressors depending on whether they 
mediate transcription regulation or repression in a given cell type and target gene 
context. Binding of coactivators to NRs is mediated by one or more of its activation 
domains AFs. Several coactivators have been show to interact with the AF-1 function of 
nuclear receptors as it is the case for the TATA box-binding protein (TBP) and the c-
AMP response element binding protein that have been shown to interact directly with 
the AF-1 region of GR2, 78, 181. The mechanism of these interactions is still poorly 
understood due to lack of structural or sequence homology among the coregulators. All 
recently studied showed that AF-1 displays a lack of structural order in solution. 
Interaction of these regions with coregulators seem to induce a fold into more ordered 
structures as it is the case for the ERα terminal domain and the TATA box-binding 
protein (TBP). According to this folding-induced mechanism the activation domain 
would firstly bind to the coactivator via weak electrostatic interactions. Secondly, 
hydrophobic interactions would direct the formation of a more stable complex where the 
activation domain adopts the conformation that is optimized for that interaction partner 
5, 181
. 
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2.3 The C Domain – DNA Binding Domain 
 
2.3.1 The structure    
 
The C domain is the highest conserved domain among nuclear receptors. It contains the 
DNA-binding domain (DBD) responsible for the specific-sequence DNA recognition. 
Several three- dimensional structures have been solved for nuclear receptors DBDs 
either by X-ray crystallography or nuclear magnetic resonance (RMN)100. All available 
NMR structures show that DBDs are monomers in solution (i.e. ERα and GR DBDs) 
and that they are poorly structured. On the contrary DBDs in complex with DNA is 
highly ordered104, 158. One of the features of the DNA-binding domain consist in two 
zinc finger motifs, each constituted of four conserved cystein residues tetrahedrally 
coordinating a Zn2+ ion. Within the DBD four sequence elements (the P, D, A and T-
boxes) have been identified to be responsible for the discrimination of the target DNA 
and the functionality of the domain (Fig.2). Residues constituting the P-box are 
responsible for selective response element recognition as in the case of the 
discrimination between the EREs and the GREs157. Three-dimensional structures 
demonstrated that in GR and ER homodimers the D-box stabilizes the dimerization 
interface57 and selects the length of the spacer between the two hemi-sites of the 
palindrome117. The C-terminal extension of the C- domain (CTE) harbours the A and T 
boxes and is critical for monomer DNA binding117 and discrimination of the spacing 
distance between the two halves of the palindrome as demonstrated for the RXR-RAR 
and the RXR-TR heterodimers74, 143. The core of the DBD is constituted by two 
amphipathical α-helices (N-terminal H1 and C-terminal H2), packed at right angles and 
responsible for the recognition of the hemi-site of the DNA response element100 . Side-
chains amino acids of the H1 establish interactions with each DNA major groove half 
site whereas H2 contributes to the stabilization of the overall structure8, 104. The NMR 
structure of RXR (DBD) and crystal structure of TRβ-RXRα (DBD) show that the CTE 
forms an additional α-helix H3103. 
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2.3.2 DBD interaction with DNA    
 
All nuclear receptors regulate transcription by binding to specific DNA sequences, 
known as Hormone Response Elements (HREs) and located at the 5’ end of target 
genes. Extensive sequence analysis of HREs revealed that nuclear receptor recognize 
derivatives of the six base pair DNA sequence 5’-PuGGTCA (Pu =A, G). Nuclear 
receptors can bind to their response elements as monomers, homodimers or 
heterodimers. At present only orphan receptors such as NGFI-B and SF-1 and steroid 
nuclear receptors such as TR and GR are known to bind to DNA as monomers70, 88, 98, 
100, 142, 185
. In this case the DNA core motif contains an extra A/T-rich sequence at the 
5’end and two subfamilies of NRs binding as monomers can be identified by their 
discrimination for 5’-AAA or 5’-TCA extension (NGFI-B and SF-1 subfamilies 
respectively). The Helix H3 at the CTE of the DNA-binding domain plays an important 
role for the stabilization of the monomeric DNA-binding nuclear receptors as it 
Fig.2- Schematic illustration of the RXR DNA binding domain (DBD). The regions 
involved in the response element selection are represented by the highlighted boxes (P, D, T, 
A) and involve two zinc-finger motifs and a C terminal extension (CTE). The P box is part 
of the helix H1, the D box is localized in the second zinc finger while the T and A boxes are 
located in the CTE. 
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provides additional interactions with the DNA’s minor groove upstream of the hemi-site 
recognition core194. 
Most of nuclear receptors bind to DNA as homo-heterodimers. Their RE is constituted 
by a duplication of the core recognition motif and the two half-sites can arrange as 
Palindromes (PALx), Direct Repeats (DRx) or Everted Repeats (ERx) where the x 
indicates the base pairs separating the two half-sites. 
Steroid receptors as GR specifically bind as homodimers to REs that are the duplication 
of the 5’-PuGG (T/A) CA core motif, as palindromes or everted repeats with 3 base 
pairs spacing. Estrogen Receptor is an exception as it can bind to widely spaced direct 
repeats. The D-box in this case forms a DNA induced dimerization interface and is 
responsible for the length selection of the spacer between the two half sites of the 
palindrome171. 
Non steroid receptors as VDR, RAR, RXR, and TR can bind as homodimers or 
heterodimers to the response element 5’-PuGGTCA arranged as direct or inverted 
repeats. The formation of heterodimers is strongly favourable as it brings new elements 
into the response elements repertory, increases the efficiency of DNA binding and 
transcriptional activity in cells in vivo50. RXR plays a double role as it can either form 
homodimers or act as promiscuous partner in the formation of heterodimers with VDR, 
RAR, RXR, and TR. The nature of the RXR partner in the heterodimer will dictate the 
preference for the length of the spacer in the direct repeat response elements as 
schematically represented by the 1-to-5 rule115 (Table2). 
It must be pointed out that the same receptors can adopt a specific binding fashion 
according to the specific response element. 
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Table2- Schematic representation of the 1-to-5 rule115. 
 
 
2.4 The D Domain- Just a hinge? 
 
The D region of nuclear receptors is less conserved than the adjacent DNA-binding and 
ligand- binding domains. D domain is classically believed to serve as a flexible hinge 
allowing the rotational flexibility of the DBD to respect to the LBD and the formation in 
both of the domains of dimerization interfaces. Nevertheless an increasing number of 
studies provide evidences for the D region implication into ligand-induced enhancement 
of transcription and cellular localisation.  
The cellular localization of a nuclear receptor is a result of the shuttling between the 
nucleus and the cytoplasm. Functional nuclear localisation signals (NLS) are 
responsible for the shuttling of cytoplasmic proteins to the nucleus. Deletion mutants of 
PR were observed to display a different cellular localization thus suggesting NLS 
implication in nuclear receptors shuttling76, 116. Nuclear receptors hinge region also 
contains a lysine motif that is conserved between phylogenetically related NRs. Lysine 
residues within this region are acetylated in vivo in ERα and are selectively acetylated 
Spacer=X 
(NTs) 
RE Acronym Receptor 
Complex 
1 DR1 RXRE, 
PPARE, etc. 
PPAR-RXR,     
etc. 
2 DR2 RARE RAR-RXR 
3 DR3 VDRE RXR-VDR 
4 DR4 TRE RXR-TR 
5 DR5 RARE RXR-RAR 
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by the coactivator p300 in vitro. Mutations of the ERα and AR conserved lysine motif 
have been shown to occur respectively in breast cancer and in prostate cancer179. 
 
 
2.5 The E Domain- Ligand binding domain  
 
2.5.1 The structure 
 
The C-terminal half of nuclear receptors encompasses the Ligand Binding Domain 
(LBD). The LBD is a highly structured module that encodes for different functions most 
of which have a ligand-dependent activity. Most importantly it harbours the ligand-
dependent transactivation function (AF-2), but it also contains large dimerization 
interfaces and cognate boxes responsible for the interaction with coregulator proteins74. 
Despite displaying a low sequence identity for the LBD domain (below the 30% for 
RARγ and RXRα) all available structures of nuclear receptors LBDs describe a highly 
conserved folding25, 31, 74, 146, 177 consisting in a three-layered sandwich of 11-12 
antiparallel α-helices (H1, H3-H12). The central layer, formed by helices (H4, H5, H6, 
H8, and H9), is comprised between the first layer (H1 and H3) and the third one (helices 
H7 and H10). H2, followed by an omega loop, establishes the connection between H1 
and H3 but is not retrieved in the folding of all nuclear receptors. This is the case for 
RARγ and TR where the H1-H3 connection is made by a longer Ω-loop. Short loops are 
found also in the region between H5 and H10 and at the C-terminal end in proximity of 
H12.   
A “common signature” in the LBD of all nuclear receptors, represented by a conserved 
20 amino-acid sequence (F, W) AKxxxxFxxLxxxDQxxLL, is found in the region 
between the end of H3 and H5. 
The carboxy-terminal region of the LBD encompasses the ligand dependent 
transactivation function AF-2. Within this region, an activation domain AF-2 AD has 
been identified (corresponding to the amphipathical helix H12) which demonstrated to 
possess a weak autonomous transcriptional activity in the absence of the ligand and to 
be structurally and functionally conserved among NRs. Mutations in this region do not 
affect ligand or DNA binding nor dimerization but prevent ligand dependent 
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transcriptional activation of AF-2 and efficient recruitment of coactivators to the 
receptor44, 45, 49, 74. 
The first crystal structures for unliganded (apo) RXRα and liganded (holo) RARγ LBDs 
revealed that hormone binding induces profound conformational changes in the receptor 
leading to the repositioning of H12 in the “agonist conformation”: H12 is folded up on 
H4 and seals the ligand binding pocket stabilizing the ligand in a “mouse-trap” model 
fashion (Fig.3). Repositioning of H12 generates a hydrophobic groove where 
coactivators can bind and activate the receptor for transcription25, 31, 71, 74, 146, 187. 
 
 
2.5.2 The agonist conformation  
 
Crystal structures for apo-RXRα, holo-TR and holo-RARγ LBDs reveal a common 
overall folding25, 51, 74, 146.  Nevertheless several important differences can be pointed out 
when comparing the structures for the apo- to the holo- receptors. Ligand binding to the 
receptor triggers a drastic conformational rearrangement that leads to the alignment of 
H10 with H11, the flipping-up of H12 that now is tighten against H4, and the release of 
the L11-12 loop. According to the “mouse-trap model”, H12 in its final agonist 
position, seals the ligand binding cavity and orients its hydrophobic residues toward the 
buried ligand5, 92, 100, 122, 187. 
Positioning of H12 in its agonist conformation generates the correct surface for 
coactivators recognition and binding and therefore is essential for nuclear receptor 
transcriptional activation. 
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Fig.3- The mouse trap model. 
A comparison between the crystal structures of the apo-RXRα (LBD) and the holo-
RARγ (LBD) shows the ligand-induced conformational change leading to the transcriptionally 
active form of NRs. According to this model, the ligand binding triggers a “mousetrap” 
mechanism in which H11 is repositioned in the continuity of H10 and the H12 folds up and 
seals the ligand binding cavity.  
 
 
2.5.3 The antagonist conformation  
 
Crystal structures of the estrogen receptor ERα LBD bound to raloxifen (RAL)31 or to 
the 4-hydroxytamoxifen (OHT)160, as well as the crystal structure of RARα in complex 
with the ligand BMS614 showed that helix H12 can adopt an “antagonist conformation” 
in which it is rotated by 130° and shifted by 10Ǻ towards the receptor body to respect to 
the agonist conformation. Sterical hindrance of some ligands seems to induce this 
antagonist conformation in which H12 occupies the cleft originated by H5 and the C-
terminal end of H3, a position that is reserved to the NR box peptide in the agonist 
bound LBD receptor31, 100. Ligands that induce non-holo H12 conformations are 
Holo-RARγ (LBD) Apo-RXRα (LBD) 
H11 
H10 
H12 
H10 
H11 
H12 
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“antagonists”. They prevent the formation of the NR-coactivator interface and the 
receptor transcription activation.  
Cases of partial antagonism in which the ligand displays only a part of the “bona fide 
antagonist” features, have been reported. In these cases the receptor H12 adopts an 
antagonist position upon ligand binding nevertheless a weak transcriptional activity is 
detected. This is the case for RARα/RXRαF318A bound to oleic acid26. 
 
 
2.5.4 The ligand binding pocket 
 
The ligand binding pocket (LBP) is buried inside the receptor within the bottom half of 
the LBD. LBP is delimited by a three helices layer composed by H3, H7and H10 and it 
is sealed, in the holo-receptor, by H12, at the completion of the mouse trap mechanism.  
Most of the residues that look onto the LBP contribute to the mainly hydrophobic 
environment. Only few polar residues are present at the end of the cavity and are 
conserved among the same  
family of nuclear receptors, suggesting their role in guiding the ligand anchoring at 
specific positions or in conferring ligand selectivity to the pocket31, 175. As an example, 
an arginine residue, located in H5, is conserved among RARs, RXRs and steroid 
receptors. This residue establishes hydrogen bonds with the carboxyl group of retinoids 
in RAR and RXR or with the A-ring phenolic hydroxyl group in ER and serves as a 
guide for the ligand correct positioning into the cavity25, 31, 146. The crystal structures of 
the LBDs of multiple nuclear receptors have been solved. Information provided by the 
crystal structures of holo-RARγ LDB and apo-RXRα LBD revealed a common fold  for 
the LBD that adopts an anti-parallel alpha helical "sandwich" conformation as 
previously described. Crystal structures for RARγ, TRβ and VDR LBDs show that the 
ligand binding pocket fits perfectly the cognate ligand shape thus offering the maximum 
number of hydrophobic contacts and contributing to the stability and the selective 
recognition of the ligand. In some cases RAR (α, β, γ) only three residues are 
responsible for the receptors isotype-selectivity towards retinoids146. The ligand binding 
pocket for steroid hormones such as PPAR γ is much wider then the ligand and accounts 
for the great variety of ligands that can be bound. The ligand recognition is driven, in 
these cases, by specific contacts rather then a concert of hydrophobic interactions128. 
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2.5.5 The dimerization interface 
 
Crystal structures for LBD dimers of several NRs have recently been solved.  
As predicted by early mutagenesis studies H10 plays a central role in the formation of 
the dimers. Homo and heterodimers display a canonical structure with H10 constituting 
the backbone of the interface. Further stabilization is provided by interactions involving 
H7, H9, and H11 as well as loops L8–9 and L9–10(Fig.3b). Due to their intrinsic 
asymmetry the heterodimers interface covers approximately the 10% of the entire 
nuclear receptors surface compared to the 15% of the homodimers26, 31, 64, 92, 128. 
Structural information was integrated in an extensive sequence alignment analysis 
aimed at elucidating the mechanism that regulates the association of nuclear receptors as 
homo or heterodimers. Two classes of nuclear receptors have been identified that 
selectively conserve either the residue at position 93 (R93 in 91% and K93 in 5% in 
homodimers) or the arginine at position 62 (R in 98% in heterodimers). Homodimeric 
NRs belong to class 1, heterodimeric NRs belong to class 2.  
Class-specific salt bridges network stabilize the receptors structures. Salt bridge 
connecting H8 to the loop 9-10 (C-term for class1, N-term for class 2) is conserved in 
both classes and confers stability to the dimer by blocking the loop in the correct 
conformation. Class 2 is also provided with a salt bridge connecting the conserved 
residue E42 (kink H4-H5) with R62 (loop 8-9). This specific interaction could explain 
why RXR heterodimers are more stable than the homodimers26, 28. 
        
 
Fig.3b- Structure of the RARβ/RXRα heterodimer. (a) H10 constituting the backbone of the 
interface, (b) Further stabilization is provided by interactions involving loops L8–9 and L9–10.  
H10 
90° 
H10 
Loop 8-9 Loop 9-10 
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2.6 The F Domain 
 
2.6.1 The structure 
 
The F domain is located at the C-terminal part of the nuclear receptor and it correspond 
to the region extending from the LBD helix H12 right to the end of the receptor. Only 
some nuclear receptors possess this domain which displays a low degree of 
conservation among NR and even within the same family. Few structures have been 
solved for this domain so far. Crystal structure for progesterone receptor (PR) indicates 
that the F domain extended conformation is stabilized by interactions with residues 
belonging to the ligand binding domain H10184. 
 
2.6.2 The function 
 
The biological function of the F domain within NR is not well known. Nevertheless 
recent studies carried onto the oestrogen receptor (ER) have demonstrated that 
truncation of F domain does not affect transcriptional activation in response to estradiol 
E2.  Following investigations revealed that the F domain deletion does not affect 
binding to the receptor of estrogens or antiestrogens not the binding of the receptor to 
their DNA REs120, 134. A large F domain is also demonstrated to prevent the interaction 
between the nuclear receptor hepatocyte nuclear factor 4 a1 (HNF4α1) and its 
coactivator GRIP1161. Analysis of the interaction between GR or TRβ  and the p160 
cofactor also suggests that their extended F domains prevent the receptors from 
recognizing the coactivator NR-box45. 
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3. How do NRs activate transcription? 
 
The ability of DNA-bound NRs to interact with the basal transcriptional machinery and 
activate the transcription of target genes is mediated by Transcription Intermediary 
Factors (TIFs), namely corepressors and coactivators.  
 
 
3.1 Coactivators 
 
Early squelching experiments, meant to investigate protein-protein interactions, were 
carried out onto nuclear receptors. These experiments demonstrated that several proteins 
interacted with nuclear receptors. Coactivators were identified as the common limiting 
factors capable of inhibiting the transcriptional activity of an agonist-bound NR when 
this interacts with another (or an excess of the same) NR. Corroboration of this 
hypothesis came from the observation that the coactivators acted in ligand-dependent 
manner and did not exert their activity onto transcriptional inactive NR (mutants or non 
holo- receptors)71.  
Some of these proteins have the character of prototypical coactivators. They enhance 
transcription activation by scaffolding the assembly of basal transcription factors into a 
stable preinitiation complex whereas other coactivators modulate nuclear receptors 
activity by exert different functions. 
 
 
 3.2 The coregulator boxes 
 
The interaction between NRs and coactivators is mediated mainly by the AF-2 region of 
nuclear receptors10. Extensive biochemical analyses enlightened that H12 integrity is 
essential for transactivation activity of NRs and that any deletion or mutation in this 
region would abrogate transcription of target genes31, 44. 
Previous mutagenesis experiments demonstrated that additional residues belonging to 
helices H3, H5, H6 and H11 are also involved in the recruitment and stabilization of 
coactivators to NRs79, 131.  Subsequent crystal structure of TRβ LBD bound to the 
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coactivator GRIP1 revealed that in the agonist-bound receptor helix H12 and conserved 
residues from H3, H4, and H5 of the nuclear receptor LBD originate a hydrophobic 
groove that interacts with the highly conserved motif (LxxLL) of the coactivator 
identified as “NR box peptide”.  
Two highly conserved residues (Lys 301 (H3) and a Glu 471 (H12)), at the surface of 
the LBD, make hydrogen bonds with Leu 1 and Leu5 from the LxxLL motif serving as 
a clamp that orients and locks the LxxLL peptide in the correct position and allows the 
hydrophobic interaction between the conserved leucines of the coactivator motif and the 
receptor hydrophobic groove. The interaction between amphipathical α-helices LxxLL 
motifs and the hydrophobic groove is highly conserved among NR-coactivator 
suggesting a common mechanism for coactivators binding to the receptors5, 25, 31, 45, 128, 
146, 160, 187
, whereas sidechain sequences outside the   hydrophobic groove of the NR 
LBD or at double ends of the LxxLL motif generate receptor and binding mode 
selectivity45. The coactivator SRC-1 binds to ER with a single LxxLL motif whereas 
combinations of two motifs are required for the activation of AR, TR, RAR, and PPAR. 
Co-repressors binding to nuclear receptors shows close similarities to co-activators 
binding fashion. Co-repressors are recognized by a short amphipathical α-helical motif 
called “CoRNR” and mutational studies reveal that they interact with NR surfaces that 
are topological very similar to that recognized by NR coactivators but do not involve 
H12124, 132. 
The discovered interaction between TIF2, a member of the p160 family, and the N- 
terminal region of ER and AR as well as the ligand-dependent interaction of different 
components of the coactivator TRAP/DRIP with both the AF-1 and AF-2 domains of 
GR suggested the identification of a second binding site for coactivators, located in the 
A/B domain of nuclear receptors. Synergy between the AF-1 and AF-2 activation 
domains with coactivator would result in an enhancement of the transcriptional activity 
of NRs14, 81. Due to the high sequence variability of the A/B domain, binding of 
coactivators to this region involves only glutamine-rich regions of the coactivator16. 
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3.2.1 The p160 family of Coactivators 
 
The most abundant class of nuclear receptors-interacting proteins is composed by 
proteins with a molecular weight of 160 KDa, the p160 family. P160 coactivators share 
a high sequence similarity and possess intrinsic histone acetyltransferase activity 
(HAT),38, 164. HAT activity addresses the carboxy-terminal region of the coactivator and 
histones H3 and H4. Prototypical coactivators are molecules that help the interaction 
between nuclear receptor and the basal transcription machinery. It is commonly 
believed that recruitment of coactivators upon ligand binding to the receptor leads to 
histones acetylation and chromatin remodelling and allows the formation of a stable 
preinitiation complex that promotes in turn transcription activation.  
 
 
Cloning allowed the partition of the p160 family in three distinct classes: SRC-1/NCoA-
1, TIF-2/GRIP-1/NCoA-2 and p/CIP/ACTR/AIB1/TRAM1/RAC371.  
The steroid receptor coactivator SRC-1 was the first to be identified. It acts as bona fide 
coactivator with several nuclear receptors as GR or ER, and non-steroid group II 
receptors such as VDR, PPAR, TR, and RXR and exerts his function in an agonist and 
AF-2-dependent manner, stimulating the transcriptional activity of the receptor. The 
mouse homolog of SRC-1 is known as NCoA-1 exhibits a NH-terminal extension.  
Immunoprecipitation experiments showed that a large part of the p160 family is 
constituted by SRC-2 coactivators, the TIF-2 in humans and the homologous GRIP-1 or 
NCoA-2 in mouse. This second class of p160 coactivators also acts prototypical 
coactivators enhancing the transcriptional activity of the cognate nuclear receptor. This 
two classes of coactivators are 30% identical overall and a high degree of homology has 
been observed in correspondence of three regions: the PAS domains at the N-term end 
of SRC-1 and TIF-2 which mediate homo and heterodimeric interactions, the central 
region of SRC-1 and TIF-2 containing a high percentage of serine and threonine 
residues and the C-term end has been found to interact with PR in the case of SRC-1. 
The third class of p160 proteins, named SRC-3, is composed by ACTR, AIB1, RAC3, 
or TRAM-1in humans and p/CIP in mice. The members of the third family are very 
similar to the coactivators from the first two subfamilies but additionally they act as 
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bona fide coactivators for several different transcription factors including activators of 
transcription (STAT-1) and the cAMP response element binding protein (CREB).  
 
 
3.2.2 CBP/p300 Cointegrators 
 
CBP and p300 are large proteins that were previously discovered to work as essential 
coactivators for the transcription by AP-1 proteins. Subsequently it was found that CBP 
and p300 also act as coactivators for many classes of transcription factors as ER, RAR, 
RXR and TR5. The strong implication of CBP and p300 in nuclear receptor 
transcription activation is witnessed by several experimental results. Overexpression of 
these coactivators enhances the transcriptional activation of the cognate nuclear receptor 
and retrieves the inhibition of GR and RAR onto AP-1 activity as the result of the 
competition between AP-1 and the nuclear receptor for CBP/ p300.  
As CBP/p300 binds nuclear receptors at the C-terminus and p160 coactivators at the N-
terminus, ternary complexes can be formed between coactivators and nuclear receptor 
as in the case of CBP and SRC-1 which interact together in the activation of PR and ER. 
CBP and p300 display acetyltransferase activity on free and nucleosomal histones. The 
removal of the histone acetyltransferase activity (HAT) domain from CBP and p300 
results in the loss of the transcriptional activity for many transcription factors 5, 38, 71, 164. 
 
 
3.2.3 TRAP and DRIP 
 
TRAP and DRIP are multiprotein complexes containing 14-16 proteins and ranging 
from 70 to 230 KDa in size. Binding of these coactivators as a single unit 
(DRIP205/TRAP220) occurs at the holo-receptor AF-2 domain and is mediated by a 
LxxLL motif, identical to that found in p160 coactivators5. 
Different components of the DRIP/TRAP complex interact in a hormone dependent 
fashion with both AF-1 and AF-2 domains of GR. DRIP150 binds to AF-1 surface 
whereas DRIP205 interacts with the AF-2 domain. Transcription activity of the receptor 
is enhanced by the cooperation of the two coactivators suggesting a functional link 
between GR activation domains. 
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The complex DRIP/TRAP does not display HAT activity; nevertheless it has been 
shown to enhance VDR and TR transcriptional activity in a cell free system containing 
chromatin. As DRIP/TRAP components are found in the SMACC mediator complex 
that interacts with RNA Pol II together with SRB proteins, it is believed that 
DRIP/TRAP work to recruit RNA Pol II to the target promoter58, 141.  
 
 
3.2.4 Corepressors 
 
Mutagenesis experiments performed onto TRβ LBD identified a domain called “CoR” 
box, encompassing H1, which is essential for binding of corepressors to the receptor. 
Some of the residues in this box are well conserved among nuclear receptors and 
mutation of three of them in particular (AHT) resulted in the abrogation of active 
repression83. All available crystal structures showed indeed that the conserved residues 
do not make direct contacts with the corepressor suggesting that the AHT mutation 
more likely affects the dissociation of the H1 from the LBD core122. The first 
corepressors to be identified were the silencing mediator of retinoic and thyroid 
hormone receptor (SMRT)39 and the nuclear receptor corepressor NCoR (RIP-3)83, 191.  
NCoR and SMRT interact with a variety of receptors such as TR, RAR and VDR. A 
couple of novel corepressors such as Alien and Hairless have more recently been 
isolated. Alien interacts with receptors as VDR, TR but not with retinoic acid receptors. 
Hairless, a corepressor required for the hair cycling, shows to interact with both TR and 
VDR90, 138, 139. 
Structural analysis of the first corepressors leads to the identification of N-terminal 
repression domains (RDs). RDs contain the highly conserved “CoRNR” consensus-
sequence (LXXI/HIXXXI/L) and are responsible for the interaction of the corepressor 
with several HDACs and the activation of gene silencing. C-terminal conserved receptor 
interaction domains (IDs) have been discovered to be responsible for the interaction of 
the corepressor with unliganded receptors5. 
 
Both corepressor and coactivator binding motifs have an amphipathical α-helical 
character. In addition mutation in H3, H4, H5, involved in the coactivator binding site, 
are shown to affect corepressor binding to the receptor. All these aspects suggest that 
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corepressors and coactivators bind to overlapping motifs as confirmed by the 
superposition of the agonist bound and antagonist bound LBD of PPARα124, 132, 188. 
It has been reported that integrity of H12 is inhibitory for corepressor binding and that 
ligand binding alone is not sufficient to induce the dissociation of the corepressors from 
the receptor.  
 
 
3.2.5 Transcription activation 
 
Activation of target genes transcription can be schematically described as an 
hypothetical three-step mechanism (Fig.4). Some receptors as RAR and TR can active 
repress transcription of target genes in the absence of the ligand9, 34. This “repression” 
step represents the first step in the mechanism that regulates nuclear receptor mediated 
transcription. In the absence of ligand apo-NRs are bound to HRE and are associated 
with NCoR/SMRT corepressors possessing intrinsic or acquired histone deacetylase 
activity (HDAC)39, 97. Deacetylated histones are associated with silent regions of the 
genome leading to gene silencing. In a second “derepression” step the ligand binds to 
the receptor and induces major conformational changes leading to corepressors 
dissociation and recruitment of coactivators belonging to the family of TIF2, SRC-1, 
RAC3 and CBP, p300 cointegrators. Coactivators display histone acetylase activity 
(HAT) and acetylate specific residues in the N-terminal tails of different histones 
leading to chromatin decondensation. The p160 coactivators may rather recruit histone 
deacetylase activity by physical association with histone acetyl transferases, such as 
CBP or p300, or with complexes containing such activities. Specifically, the activation 
domain AD1 of TIF2 has been demonstrated to function via the recruitment of 
cointegrator CBP176, which in turn acetylates TIF2. Besides HAT activities, NR 
coactivator complexes possess other enzymatic activities. TIF2 proteins are able of 
interacting functionally via their activation domain AD-2 with a protein 
methyltransferase38. 
Once the chromatin environment at the promoter of target genes has been decondensed 
by coactivator complexes containing members of the TIF2 and CBP families, the 
nuclear receptor recruits the RNA Pol II holoenzime via association with the 
TRAP220/DRIP205 subunit, belonging to the large multisubunit protein complex 
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known as mediator complex SMCC. The switch between coactivators and the SMCC 
complex might be regulated by the acetylation of coactivators within the HAT complex, 
resulting in their dissociation from the nuclear receptor and in the recruitment of factors 
such as SMCC, via the LxxLL motif of the TRAP220/DRIP205 subunit72, 100 
 
 
 
Fig.4- Schematic mechanism by which NRs activate the transcription of target genes. In 
the absence of the ligand RAR/RXR heterodimers, located in the cell nucleus, are bound at the 
RE of the target genes, in complex with co-repressors possessing histone deacetylase activity. 
Histone deacetylation leads to DNA condensation and repression of transcription. Binding of 
ligand induces the release of the HDAC complex and induces the recruitment of co-activators 
possessing histone acetyltransferase activity (HAT). The subsequent chromatin decondensation 
due to histone acetylation leads to the recruitment of the RNA Polymerase II holoenzyme and 
the Mediator complexes (MEDs) and leads to transcription activation. 
 
 
 
 
 
 
 37 
4. Posttranslational modifications on NRs 
 
Nuclear Receptors are targets for multiple posttranslational modifications such as 
acetylation, ubiquitylation and phosphorylation55, 61, 179 which act in concert to regulate 
NR-mediated transcription. 
Nuclear receptors such as AR and ERα are target for histone acetyltransferase in vitro 
and in vivo. The ERα acetylation motif is conserved between different species including 
vertebrates, arthropods, and nematodes and between phylogenetically related nuclear 
receptors such as TR, RAR, PPAR, VDR, GR, PR, HNF4 and SF1, suggesting that 
direct acetylation of nuclear receptors may participate to additional signalling 
pathways60, 62,179. 
Transcription regulation of NRs appears to be coupled with degradation of these 
proteins by the ubiquitin–proteasome pathway18, 22, 43, 55. Ubiquitination of steroid 
receptors can depend on the ligand binding to the receptor as for MR190, ER (α, β)33, 
GR178 and PPARα18 or act constitutively as for PR and AR.  Ubiquitylation of PR 
depends on the phosphorylation of the residue S294140 whereas for AR poly-
ubiquitylation impairs the activity of the receptor by directing it to the proteasome109 
and monoubiquitination of the receptor leads to AR stabilisation and transcriptional 
activity enhancement33.  
Recent investigations showed that nuclear receptors are also target for methylation. 
ERα is methylated in the hinge region by Set7 at the consensus recognition sequence 
[R/K][S/T]K42, which displays high similarity with the conserved acetylation motif 
found in nuclear hormone receptors60. ERα is also methylated at the DNA-binding 
domain at residue R260 by PRMT1. Methylation of ER stabilises the receptor allowing 
its efficient recruitment to target genes166. The hepatocyte nuclear factor 4 is also 
methylated by PRMT1at the DNA-binding domain leading to enhanced binding to 
target genes11. Recent studies enlightened that mouse RARα trimethylated at Lys347 
located in the ligand binding domain (LBD) leading to enhanced interactions with 
coactivators as well as its heteordimeric partner RXR85. 
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4.1 Nuclear Receptors Phosphorylation 
 
Phosphorylation has been the most extensively studied posttranslational modification 
due to its established participation to the signalling cross-talk of almost all NRs.  
Both the N-terminal and C-terminal regions of NRs contain several consensus sites for 
phosphorylation by different kinases such as cyclin-dependent kinases (CDKs), mitogen 
activated protein kinases (MPKs), and Jun N-terminal kinases (JNKs). 
There is increasing evidence that phosphorylation can finely tune nuclear receptors 
activity by disrupting the complex with other components of the transcription 
machinery, weakening the affinity for the ligand binding domain or activating the 
receptor degradation thus reducing or abolishing the receptor response to the ligand. 
Nevertheless the exact mechanism through which phosphorylation would regulate 
nuclear receptors’ activity is still unclear23, 148, 149.  
Moreover there is increasing evidence indicating that NRs phosphorylation is 
determinant in the development of several types of cancer. Most of these cancers such 
as breast, ovarian and prostate cancers are characterized by up-regulated kinase activity 
and ligand-independent transcription activation of target genes. Hyperactivity of 
MAPKs leads to the ligand-independent phosphorylation of ERα and AR and to 
anomalous growth of breast and prostate cells. Hyper-phosphorylation of RXR prevents 
transcription of genes responsible for the control of cell growth and it is probably linked 
to development of hepatocellular carcinoma. Finally hypophosphorylation of RARs by 
the cyclin-dependent kinase cdk7 results in a deficient response to retinoic acid and 
leads to a severe genetic disease known as Xeroderma Pigmentosum characterized by 
photosensitivity, premature skin aging and skin tumours development23. Up to date no 
structure is available for a phoshorylated receptor19, 150. 
 
Most of nuclear receptor phosphorylation sites are localized within the N-terminal 
region. The number of phosphorylation sites is highly variable depending on the type of 
nuclear receptor. As an example, Progesterone receptor (PR) contains up to 13 
phosphorylation sites in the N-terminal A/B region, Retinoic acid receptors (RARs) and 
PPARs contain one or two phosphorylation sites whereas VDR represents an exception 
and is not phosphorylated at his NTD. Most of the phosphorylation sites are constituted 
by serine and proline-rich motifs, corresponding to consensus sites for proline 
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dependent kinases such as cyclin-dependent kinases (CDKs) and MAP kinases (Erks, 
JNKs and p38MAPK). Phosphorylation at the N-term can occur in response to hormone 
binding or in the absence of ligand as the response to a variety of signals. As an 
example, unliganded estrogen receptor alpha (ERα) is phosphorylated at Ser 118, 
located in AF-1 by the mitogen-activated protein kinases (MAPK). This 
phosphorylation affects the receptor ability to dimerize, bind the ligand and the DNA, 
interact with coregulators and finally activate the transcription of target genes32, 155. The 
AF-1 domain of PR, PPARs, and RARs has also been reported to be target for 
phoshorylation by MAPKs. In particular phosphorylation of AF-1 of RARγ2 is required 
for RA-induced differentiation into primitive endoderm, whereas phosphorylation of 
AF-1 and AF-2 in RARα1 and RARγ is required for differentiation into parietal 
endoderm148, 169.  RXRα is targeted by c-Jun N-terminal kinases (JNKs) which belong 
to the MAPKs family and ERα and AR are phoshorylated at their N-terminal region by 
Akt or PKB kinases whose activation is determinant in cell survival and proliferation27, 
149
. Ligand-bound NRs including ERα, RARα, RARγ and AR have been reported to 
interact with the general transcription factor TFIIH, a multiprotein complex that acts as 
mediating transcription activator. TFIIH is composed of nine subunits, including cdk7 
which displays a cyclin-dependent kinase activity. As the consequence of the interaction 
with TFIIH, ERα and RAR (α, β, γ) are phosphorylated at their N-terminal region by 
TFIIH subunit cdk713, 37, 86, 149. In most cases (i.e. ERα, PPARα and AR) the 
phosphorylation at the N-terminal region helps the assembly of a functional 
transcription machinery by favouring the recruitment of coactivators, chromatin 
remodellers, and general transcription factors that enhance the response to the ligand 
and consequently the expression of retinoid target genes149. Nevertheless there are cases 
in which phosphorylation of the N-terminal region has been correlated with the 
inhibition of the transcriptional activity of the receptor, as it is the case for VDR, or 
with the promotion of NRs degradation by the ubiquitin proteasome pathway as it is the 
case for GR, PPARγ, RAR20, 23, 30, 32, 68, 69, 159. In the latter case nuclear receptor 
phosphorylation would allow tuning the length and the intensity of the receptor 
response to the ligand.  
 
Nuclear receptor LBD is also a target for phosphorylation. Phosphorylation of this 
domain involves several kinases. Tyrosine kinases are responsible for the 
 40 
phosphorylation of ERα and RXRα whereas cAMP-dependent protein kinase A (PKA) 
and MSK-1 share the S369 phosphorylation site of RARα. The cAMP-dependent 
protein kinase A (PKA) is also responsible for RARγ phosphorylation at S371 30, 148, 149.  
Phosphorylation at the C-term domain is most often directly involved in the 
enhancement of the receptors transcriptional activity as in the case of ER and PKA. 
ERα phosphorylation at tyrosine 537 by Src kinases enhances ERα transactivation 
probably due to conformational changes that modify ligand binding properties. 
RARα phosphorylation by PKA also enhances the transcriptional activity of the 
receptor and has been shown to favour receptor heterodimerization and coregulators 
binding.  
Phosphorylation of coregulators is involved in the crosstalk between NRs and other 
signalling pathways. It has been demonstrated that phosphorylation of coactivators such 
as p300/CBP149 and SRC-1151 favourites their interaction with the liganded receptor and 
the recruitment of chromatin modifying complexes. Phosphorylation of corepressors, on 
the other hand, has been related to translocation of the receptor out of the nucleus and 
inhibition of transcriptional activity82. 
 
 
5. Cellular Localisation 
 
NRs are classically divided in two classes depending on their localization within 
different subcellular compartments.  
The “translocating” receptors, as most of the steroid hormones (AR, GR, PR, MR but 
not ER), are predominantly found in the cytoplasm in the absence of ligand and they 
move to the nucleus upon cell stimulation by the hormone. In the cytoplasm and in the 
absence of hormone stimulation, the receptor is inactive and it forms a large complex 
with chaperones proteins, notably members of the heat shock protein Hsp90 machinery, 
which appear to help the correct folding of the receptor LBD77. Binding of the cognate 
ligand to the receptor induces dissociation of the receptor-chaperone complex and 
exposes the receptor nuclear translocation signals (NLS). Interaction between NLS and 
the nuclear pore complex would determine the subsequent translocation of the receptor 
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to the nucleus.  The “Nuclear” receptors as RAR, VDR and TR are mostly found in the 
nucleus either in presence or absence of the ligand. 
 
Recently several exceptions to this widely accepted model have been documented. The 
steroid receptor ERα exchanges its Hsp-complexed and free form in a ligand dependent 
manner, nevertheless its presence is confined to the cell nucleus77, 136. TR is as a steroid 
receptor and its constant presence in the nucleus was always explained by the receptor 
ligand-independent ability to bind DNA. Recent experiments in living cells 
demonstrated indeed that a large amount of the total TR present in the cell is found in 
the cytoplasm77, 129. Finally several receptors such as PR, TR and GR receptors have 
been shown to gather in “accumulation points” within the nucleus upon cell stimulation 
with hormones. All these results suggest that nuclear receptors localization within cell 
does not simply depend on the receptor NLS recognition or the ligand-independent 
capacity of the receptor to bind to DNA but is rather a dynamical and multifactor 
process. 
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6. Retinoids  
 
Vitamin A and derivatives are commonly referred to as retinoids.  
Retinoids are important signalling molecules that explicate their function through the 
binding to specific nuclear receptors (RARs and RXRs) and their activation for 
transcription of retinoid target genes. Retinoids are essential for the life of all 
organisms. They control vital processes such as cell growth, differentiation and death 
and regulate functions such as vision, reproduction, embryonic growth and 
development.  
Vitamin A deficiency (VAD) has been correlated to severe ocular features known as 
Xerophthalmia and reduced resistance to infections. Excess of vitamin A also has 
deleterious effects on the organisms and affects skin, bones, nervous and circulatory 
system and embryonic development152, 165. 
Several studies based on animal models demonstrated that retinoids are efficient 
chemotherapeutic agents. Retinoids and especially retinoic acid compounds are 
currently used in the treatment of acute promyelocytic leukaemia (APL), several types 
of cancers and precancerous lesions such as oral leukoplakia, cervical dysplasia and 
xeroderma pigmentosum (an inherited predisposition  to ultraviolet-induced  cancers)3, 
96, 121, 165
. 
 
 
6.1 The chemistry of retinoids 
 
According to the IUPAC definition the term Vitamin A encompasses all compounds 
displaying the biological activity of retinol.  
Long controversies have characterized the definition of the term “retinoids”. The 
currently accepted definition is an integration of the original IUPAC definition and 
considers the class of retinoids constituted by “retinol analogs (with or without biologic 
activity) but also of several compounds that are not closely related to retinol but elicit 
biological vitamin A or retinoid activity”. 
Retinoids are derivatives of the primary alcohol all-trans retinol. All-trans retinol is a 
lipophilic ligand that is carried in plasma by binding proteins but it possesses a partial 
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hydrophilic character. These features allow all-trans to efficiently diffuse through 
hydrophilic cellular fluids as well as hydrophobic membranes19. Retinoids are mostly 
present in animal tissues as retinyl palmitate or other fatty acid esters such as retinyl 
stearate or retinyl oleate and occur predominantly in the all-trans configuration (Fig.5). 
The role of all these retinoids is not known yet but they are likely to represent 
intermediates in the synthesis or degradation of retinol.  
Retinoids are unstable in presence of oxygen and light. Exposure to either of the two 
elements leads respectively to degradation or isomerization. For these reason retinoid 
solutions must be handled in inert atmosphere and must be sheltered from light 75. 
 
 
6.2 Vitamin A metabolism 
 
Animals cannot synthesize vitamin A. They guarantee the appropriate uptake of vitamin 
A by dietary assumption of caroteinods, as the product of the metabolism of fungi, 
algae, micro organisms and bacteria, subsequently converting them into retinal. As an 
alternative, animals can obtain retinoids directly from other animals that have already 
carried out the conversion into retinol or retinyl esters. Retinyl esters and retinol 
accumulate especially in fish, mammalian liver, eggs yolk and milk.  
Carotenoids are absorbed in the small intestine cells (enterocytes) by passive diffusion. 
Here β-carotene is enzymatically converted into retinal which is in turn reduced to 
retinol107. Dietary retynil esters instead are enzymatically reduced to retinol before 
being absorbed by the enterocytes. In the enterocytes retinol is bound to a protein called 
cellular retinol-binding protein type II (CRBP-II). This protein solubilizes retinol and 
promotes the enzymatic re-esterification of the large majority of the retinol to retinyl 
esters. Retynil esters are stored and secreted into the intestinal lymph clustered into 
large lipoprotein complexes called chylomicrons21.  In this form retinyl esters and 
unesterified retinol are uptaken into the hepatocytes and stored in the so-called stellate 
cells. Retinol is mobilized by these cells in a controlled manner and oxidized to all-trans 
retinoic acid which has a particular relevance as it activates the RAR and RXR 
transcription factors. Other metabolise of Vitamin A include 9-cis retinoic acid, 13-cis 
retinoic acid, 13-cis-4-oxo retinoic acid, all-trans-4-oxo retinoic acid, all present in the 
plasma126, 145. 
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   (a)           (b) 
  (c)              (d)  
  (e)           (f) 
 
Fig.5- Some of the retinoids present in human body: (a) all-trans retinol, (b) retynil palmitate, 
(c) all-trans retinoic acid, (d) 13-cis retinoic acid, (e) 9-cis retinoic acid, (f) β−carotene 
 
 
6.3 Retinoic acids 
 
Retinoic acid (RA) is a low molecular weight molecule of 300 Da. 
Despite the predominant hydrophobic character retinoic acid is partially soluble in intra 
and extra-cellular fluids. This amphipathical nature allows retinoic acid to rapidly 
diffuse and renders it a prototypical morphogen that is synthesized in localized centres 
but then explicates its function at a distance. Retinoic acid plays a central role in a 
multitude of physiological mechanism such as cellular differentiation and reproduction, 
development of the central nervous system113 and haematopoiesis41, and is implicated in 
pathological conditions such as cancer127, 174 and skin diseases56, 95, 189. The simplest 
mechanism leading to 9-cis-retinoic acid biosynthesis consists in the isomerization of 
all-trans retinoic acid.  Despite having been accepted as Vitamin A pathway signalling 
molecule, there is no experimental evidence for 9-cis retinoic acid to be an endogenous 
compound.  
Endogenous characterization of this isomer should include multiple techniques such as 
MS, NMR and UV spectroscopy and should take in account artefacts due to the 
isomerization of all-trans retinoic acid to the cis-isomer induced by day light and thiol-
containing compounds such albumin and GSH.  
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In one case the presence of 9-cis retinoic acid has been detected in the human body and 
that is following administration of a 100 fold recommended dose of retinol. These 
results do not prove the existence of endogenous retinol but could suggest that all-trans 
retinoic acid is the natural activator of the retinoid receptors while 9-cis retinoic acid 
would be produced in response to a massive administration of vitamin A and would 
account for vitamin A toxicity and aberrant RAR and RXR gene activation3, 19. 
 
 
6.4 Retinoids acid in cancer 
 
Strong experimental evidences show that retinoids prevent cancer by inhibiting 
progression of preneoplastic lesions to malignant stages4, 40, 53, 162, 163. Experimental 
studies based on animal models demonstrated that they possess a wide range of clinical 
applications and display different pharmacokinetic and pharmaceutical features. 
Isotretinoin (13-cis retinoic acid) induces the differentiation and apoptosis of tumour 
cells and inhibits the progression of pre-malignant lesions102. Isotretinoin finds 
numerous clinical applications and is used in combination with interferon alpha (IFNα) 
to treat patients with pre-malignant diseases such as leukoplakia, cervical intraepithelial 
neoplasia and xeroderma pigmentosum as well as to arrest advanced skin and cervix 
carcinomas46, 95, 119.  
 ATRA or Isotretinoin (All-trans retinoic acid) binds to RXR receptors. This retinoid is 
currently used to treat acute promyelocytic leukaemia (APL) in which myelopoiesis is 
arrested at the promyelocytic stage.  In APL a chromosomal translocation is responsible 
for the formation of the oncofusion protein PML–RARα resulting in the deregulation of 
RARα gene. Retinoic acid combined with chemotherapy restores the normal 
functionality of RARα and reactivates all the functions mediated by the retinoid 
receptor such as the induction of cell differentiation and the control of cell growth40.  
Alitretinoin (9-cis-retinoic acid) activates both RAR and RXR receptors. Experiments 
based on animal models demonstrated that 9-cis retinoic acid has a more powerful 
antitumoral activity than the all-trans isomer. It strongly promotes cell differentiation 
and suppresses the progression of breast tumours in several animal models73, 186. In 
transgenic mice expressing the oncoprotein Hras1 and treated with the tumour promoter 
PHORBOL ESTER 12,13- tetradecanoyl phorbol acetate (TPA), 9-cis retinoic acid  
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demonstrated to prevent the progression of the early stage tumours3. Despite 
experimental evidence showing that the benefits from retinoids are reversible upon 
suspension of the treatment, clinical administration of retinoids can occur only for short 
periods of time due to their high level of toxicity. Despite all-trans retinoic acid 
activates only RAR, 9-cis retinoic acid binds to both RAR and RXR and 13-cis retinoic 
acid binds to the receptors with very low affinity, the three retinoic acids interconvert in 
the human body via isomerization and act as non selective (pan agonists) activators for 
the RAR-RXR heterodimer, incrementing retinoids toxicity46. For this reason 
development of receptor-selective and isotype-selective synthetic retinoids is a major 
priority in retinoids pharmaceutical industry for clinical applications. More selective 
retinoids with lower toxicity and fewer side effects have recently been discovered. As 
an example LGD1069 (bexarotene) is the first synthetic retinoid displaying highly 
selectivity for retinoid-X-nuclear receptor to be authorized in the treatment of cutaneous 
T-cell lymphoma. LGD1069 represents a valuable substitution to the classical 
combinatorial treatment based on 13-cis and all-trans retinoic acid which demonstrated 
to be less effective and more toxic. LGD 1069 is now in Phase II clinical trials for the 
treatment of non- small-cell lung cancer93, 180.  
 
 
7. Retinoic Acid Receptor (RAR) and Retinoid X 
Receptor (RXR)  
 
7.1 RARs and RXRs transduce the signal of RA 
 
Retinoids explicate their biological function through binding to specific families of 
nuclear receptors: the RARs and RXRs. Each family is composed by three genetic 
isotypes (α, β, γ).  
Each RAR and RXR isotype has two major isophorms originated from the use of 
different promoters or alternative splicing and that differ in their N-term regions. The 
high degree of sequence homology between the isophorms of each isotype suggests that 
each isophorm has specific function105.  
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The retinoid acid receptor RAR binds both all-trans RA and 9-cis RA with Kd values in 
the 0.2-0.7 nM range1 and is transcriptionally active in the form of RAR-RXR 
heterodimers.  RXR binds 9-cis RA with Kd value of 10 nM range but display very low 
affinity for all-trans RA1, 80, 106. 
 
7.2 Retinoid response elements 
 
According to the 1-to-5 rule115 RAR, in the form of RXR-RAR heterodimer, binds to 
DR5 response elements. In these elements RXR occupies the 5’half-site whereas RAR 
occupies the 3’ one97, 114. The selectivity of the binding to the DR5 elements is 
determined by the interaction between the D-box in the second zinc finger of RXR and 
the tip of the second zinc finger of RAR193. RXR-RAR heterodimers also bind DR1 and 
DR2 response elements. In DR1 elements the polarity of the heterodimers is inverted 
(5’-RAR-RXR-3’). This is thought to account for the lack of response to retinoids 
characteristic of  RXR-RAR heterodimers bound to DR1 elements97. In RXR-RAR 
heterodimers bound to DR2 element the RAR T-box forms a surface that interact with 
and the RXR second zinc-finger192.  
 
 
7.3 RAR posttranslational modifications 
 
7.3.1 RAR posttranslational modifications 
 
Recent studies performed through mass spectrometry revealed that mouse RARα is 
target for methylation at lysine residues 347, 109 and 171 located respectively in the 
receptor LBD, DBD and hinge region. Trimethylation of RARα at Lys347 enhances the 
LBD sensitivity to retinoic acid, helps the recruitment of the cofactors p300/CREB and 
favours the interaction with the heterodimeric partner RXR84, 85. Methylation at Lys109 
involves the homologous sequence (CEGCKGFFRRS) which is conserved within the 
NR super family and different species. Recent studies enlightened that methylation at 
Lys109 enhances the full length receptor response to retinoic acid84.  
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RAR is target for ubiquitylation within the heterodimer RAR/RXR. This process leads 
to the both partners degradation by the proteasome in response to retinoids22, 68, 69, 94, 168, 
195
. Nevertheless ubiquitylation of RARγ within RARγ/RXR revealed that proteasome 
ubiquitylation could play a double role, controlling the recruitment of a functional 
transcription machinery on one hand109 and leading to the receptors degradation on the 
other hand. On the basis of this dual function the proteasome ubiquitylation has been 
purposed to regulate the functionality of RARγ/RXR heterodimers, as recently 
demonstrated for other nuclear receptors such as the estrogen and androgen receptors59, 
144
. 
 
 
7.3.2 RAR Phosphorylation  
 
The N-terminal domain of RARs is target for phosphorylation by the cyclin-dependent 
cdk7 kinase. This kinase is a subunit of CAK, a ternary complex composed by cdk7, 
cyclin H and MAT1 and belonging to the general transcription factor TFIIH. Cdk7 
phosphorylates RARα and RARγ respectively at S77 and S79 150. Recent studies 
demonstrated that the correct positioning of cdk7 and the efficiency of the receptors 
phosphorylation by cdk7 is controlled by the docking of cyclin H at a specific region of 
RARs LBD, corresponding to the loop 8–9 and the N terminus of helix 9 (aa 339-368 in 
RARγ) 24, 63. The presence of a specific binding site for cycH is thought to elicit the 
specificity of cdk7 kinase interaction with the N-terminal proline rich region of NRs 
that could in principle be phosphorylated by any proline-tyrosine kinase. The 
importance of the TFIIH mediated phosphorylation at the N-term domain of RARs has 
been enlightened by studies performed onto Xeroderma Pigmentosum (XP) patients 
suffering from an inherited predisposition to develop UV-induced skin-cancers. XP is a 
rare genetic disorder in which inherited mutations in the XPD subunit of the general 
transcription and repair factor TFIIH prevent the correct positioning of the cycH thus 
leading to hypophosphorylation of RARα NTD by cdk7 and to the receptor deficient 
response to RA. 
RARs are also target for phosphorylation by the cAMP-dependent protein kinase (PKA) 
which phosphorylates RARα and RARγ respectively at S369 and S371 (Fig.6). These 
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serine residues are located in the loop 9-10 of the LBD, in close vicinity to the cyclin H-
docking site63.  
Gaillard and al. recently demonstrated that phosphorylation of these residues by PKA 
enhances cycH binding to the receptor. Consequently, both the phosphorylation of NTD 
by Cdk7 and the transcription of RA-target genes are enhanced63. According to this 
novel molecular pathway phosphorylation by PKA would propagate c-AMP signal from 
the AF-2 domain to the AF-1 domain and would represent the first example of allosteric 
controlled communication between two domains of the same receptor. 
RARγ (but not RARα) phosphorylation at the NTD affects its interaction with the actin-
binding protein Vinexinβ whose function is still not fully understood. Vinexinβ is a 
protein containing SH3 motifs and it is thought to act as a corepressor for RARγ. In the 
absence of the ligand Vinexinβ and RARγ are both bound to the promoter region of 
RARγ target genes and RARγ is not phosphorylated at the NTD. In response to the 
ligand, TFIIH is recruited at the receptor surface and Vinexinβ is released allowing 
transcription initiation23. 
In presence of the ligand the N-term domain of RARγ is phosphorylated by the 
p38MAPK30 whereas RARα is not directly targeted by this kinase which 
phosphorylates instead the p160 coactivator SRC-3. Phosphorylation by p38MAPK 
marks the receptor for ubiquitynilation and proteosomal degradation providing a switch 
to the receptor transcriptional activation. 
 
 
 
Fig.6- RAR is target for phosphorylation at different domains. 
The N-ter domain of RAR is phosphorylated by the cyclin-dependent kinase cdk7. This kinase is a 
subunit of CAK, a ternary complex composed by cdk7, cyclin H and MAT1 and belonging to the general 
transcription factor TFIIH. Cdk7 phosphorylates RARα and RARγ at S77 and S79 respectively. RAR is 
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also target for phosphorylation by the cAMP-dependent protein kinase (PKA) which phosphorylates 
RARα and RARγ at S369 and S371 respectively.  
 
 
 
 
8. Our project 
 
This work aims at providing new structural insights to understand at atomic level how 
phosphorylation by PKA participates in nuclear receptor signalling. More specifically 
we will investigate the impact of the phosphorylation at the serine residue located in the 
loop 9-10 of the LBD on the structure of the whole RAR ligand binding domain and 
onto hCycH binding to the receptor. To this respect we will integrate X-ray 
Crystallography and Nuclear Magnetic Resonance spectroscopy (NMR) studies. Both 
these techniques can provide structure of macromolecules such as proteins and nucleic 
acids at atomic resolution and play a key role in structural biology for a detailed 
understanding of molecular functions. It is important to underline that X-ray 
Crystallography and Nuclear Magnetic Resonance spectroscopy are not competing 
techniques, they rather complement each other.  
X-ray crystallography requires single crystals and can be applied to very large 
macromolecular complexes (>100KDa), as long as suitable crystals are available.  
The most serious limitation of X-ray crystallography is given by its restriction to static 
structures. In order to acquire information about the dynamics of the molecule of 
interest it is therefore essential to combine X-ray crystallography with other techniques 
capable of providing such information.  
Nuclear magnetic resonance (NMR) represents the most suitable technique to obtain 
information concerning molecular dynamics at atomic level. NMR measurements are 
performed under conditions that can be as close as possible to the physiological 
conditions. NMR measurements not only provide structural data but can also supply 
information on the internal mobility of proteins, on protein folding and on intra- as well 
as, intermolecular processes. NMR is limited to relatively small proteins. Larger 
molecular structures (more than 30 KDa) give rise to overlapping signals that cannot be 
resolved. In these cases protein samples enriched with active isotopes 15N, 13C, 2 H are 
required. 
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The crystal structure of hRARγ has already been determined in our group146. We need 
to compare the high resolution crystal structures of the unphosphorylated RAR (LBD) 
with that of the phosphorylated receptor or with that of the S371E mutant in which the 
mutation is well known to mimic a phosphorylation event17, 89, 110. Differences in the 
structures dynamics due to the phosphorylation of the residue S371 will be then 
highlighted by nuclear magnetic resonance (NMR), the most suitable technique to 
provide information about the dynamics of macromolecules in solution at atomic 
resolution. 
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 54 
9. Protein expression and purification 
 
9.1 (His)6 hRARγ WT and h(His)6 hRARγ S371E 
 
The LBDs of hRARγ WT (178-423) and hRARγS371E (178-423) were separately 
expressed in the bacterial host (E. coli, BL21 (DE3)). Both the proteins were expressed 
in pET-15b vectors with ampicillin resistance and fused with a hexahistidine (His)6 tag 
for protein purification. In hRARγS371E a mutation was introduced at position 371 
exchanging a serine for a glutamic acid to mimic the phosphorylation of the residue17, 89, 
110
.  
 
A common purification protocol was set up for the two proteins consisting in the 
following consecutive steps:  
 
1- Metal (Ni2+) affinity chromatography  
2- Size exclusion chromatography  
 
The yield of the pure protein was respectively of 6 mg per litre of culture for hRARγ 
WT and of 7 mg per litre of culture for hRARγ S371E. Ligand binding was confirmed 
by ESI-mass spectrometry and the purity of the proteins was checked by SDS-gel 
electrophoresis. The polydispersion of the purified proteins was analyzed by dynamic 
light scattering (DLS) measurements and resulted of the 22% for both hRARγ and 
hRARγ S371E. 
Below I reported the chromatograms concerning the two-step purification of hRARγ 
WT and hRARγS371E.  
The typical metal affinity chromatogram I registered consisted of several peaks 
corresponding to different steps of the elution by increasing concentrations of 
imidazole. The size exclusion chromatogram consisted in a single major peak 
corresponding to the elution of RARγ as a monomer homogeneous pure sample. 
Both the hRARγ WT and hRARγS371E are stable in the absence of ligand. For this 
reason the proteins were purified in the absence of ligand and 9-cis retinoic acid was 
added to the purified protein, which allowed to spare a considerable amount of material.  
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The ligand is added to a two fold number of moles to respect to the moles of protein. 
The sample, sheltered form light, was let incubate for 30 min at 4°C to ensure the 
binding. 
 
 
 
 
Fig.7- Metal affinity chromatogram and SDS-PAGE of hRARγ wild type (apo) 
 
 
~ 28 KDa 
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Fig.8- Size exclusion chromatogram and SDS-PAGE of hRARγ wild type (apo) 
 
 
 
 
Fig.9- Metal affinity chromatogram and SDS-PAGE of hRARγ S371E (apo) 
~ 28 KDa 
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Fig. 10- Size exclusion chromatogram and SDS-PAGE of hRARγ S371E (apo) 
 
 
 
9.2 (GST)-hRARα, (GST)-hRARαS369E, (GST)-hRXRα 
 
The LBDs of hRARα WT (176-421), hRARαS369E (176-421) and hRXRα (223-462) 
were separately expressed in the bacterial host (E. coli, BL21 (DE3)). The three proteins 
were expressed in pGex-4T3-Gateway vectors carrying ampicillin resistance and a 
Glutathione-S-transferase (GST) tag. 
The hRARα WT and hRARαS369E were either expressed in rich medium or minimal 
media for 15N isotopic enrichment. In hRARαS369E a mutation was introduced at 
position 369 exchanging a serine for a glutamic acid to mimic the phosphorylation of 
the residue17, 89, 110.  
GST fusion cleavage was performed according to experimental requirements.  
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When GST cleavage was needed the ligand was added before purification to reduce the 
destabilisation of protein upon tag digestion and a common protocol for the three 
receptors was adopted consisting in the three following steps:  
 
1- Glutathione (GSH) affinity chromatography 
2- Cleavage of the GST fusion tag by thrombin digestion  
3- Size exclusion chromatography  
 
When experimental requirements did not include GST cleavage the purification 
protocol, adapted to the three receptors consisted in the following alternative procedure: 
 
1- Glutathione (GSH) affinity chromatography 
2- Elution of the GST fusion protein by glutathione (GSH) digestion  
3- Size exclusion chromatography  
 
The yield of the pure proteins was of 7 mg per litre of culture for both hRARα WT and 
hRARαS369E, either in unlabelled or the 15N enriched medium. The yield of pure RXR 
was of 30 mg per litre of culture.   
The binding of the ligand was checked by ESI-mass spectrometry and the purity of the 
proteins was checked by SDS-gel electrophoresis. The polydispersion of the purified 
proteins was analyzed by dynamic light scattering (DLS) measurements and resulted 
respectively of the 20% and 21% for hRARα and hRARαS369E.  
 
 
Here below I reported the SDS-PAGEs concerning the three step purification of hRARα 
WT (same for hRARαS369E and hRXRα).  
The GSH affinity chromatography consisted in the wash of the GSH beads, to which the 
GST-fusion protein is bound, and it was performed onto peristaltic pump. Enzymatic 
cleavage of the GST tag was carried on beads in presence of thrombin. The size-
exclusion chromatogram consisted in a major peak corresponding to the elution of 
RARα as a monomer homogeneous pure sample, as shown by the SDS gel and the DLS 
measurement.  When the GST fusion was cleaved the ligand was added from the cell 
lysis to increase protein stability in solution. As retinoids undergo UV-light induced 
 59 
isomerization, the purification was carried and the final protein sample was handled 
under dim light. 
 
 
                         
Fig.11- Elution of hRARα WT (holo) after thrombin digestion on beads  
 
 
                               
Fig.12- Size exclusion chromatogram and SDS-PAGE of hRARα WT (holo)  
 
 
Here below I reported the final SDS-PAGEs concerning the purification step of GST-
hRARαS369E (same for hRARα WT and hRXRα). 
The GSH affinity chromatography consisted in the wash of the GSH beads to which the 
GST-fusion protein and it was performed onto peristaltic pump.  
Elution of the GST fusion protein was carried out in presence of GSH.  
 Size exclusion chromatogram consisted in a major peak corresponding to the protein of 
interest.  
~ 28 KDa 
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Fig.13- SDS-PAGE of GST- hRARαS369E (apo) after size-exclusion chromatography 
 
 
 
9.3 hCyclin H 
 
 
The full length hCycH (1-323), was expressed in the bacterial host (E. coli, BL21 
(DE3)). The expression was carried out in pET-15b vectors with ampicillin resistance 
and hexahistidine (His)6 tag for protein purification.  
The purification protocol consisted in three main steps: 
 
1- Metal (Co2+) affinity chromatography 
2- Cleavage of the His tag by thrombin digestion 
3- Size exclusion chromatography  
 
The yield of the pure protein was of 12 mg per litre of culture.  The purity of the protein 
was checked by SDS-gel electrophoresis and MALDI-TOF mass spectrometry and 
resulted of the 95%. 
 
As previously discussed the metal affinity chromatogram consisted of several peaks 
corresponding to different steps of the elution by increasing concentrations of 
imidazole. The size exclusion chromatogram consisted in a single major peak 
corresponding to the protein of interest (chromatograms not shown). Below I reported 
the SDS-PAGEs concerning the two chromatography steps of the purification of 
hCycH.  
 
~ 54 KDa 
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Fig.14- SDS-PAGE of hCycH after metal affinity chromatography 
 
 
 
Fig.15- SDS-PAGE of hCycH after size-exclusion chromatography 
 
 
9.4 PKA 
 
The catalytic subunit of the c-AMP dependent protein kinase (2-351) was expressed in 
the bacterial host (E. coli, BL21 (DE3)). The expression was carried out in the Gateway 
vector pHGWA containing Ampicillin resistance and hexahistidine (His)6 tag.  
 
The purification protocol consisted in one main step: 
 
1- Metal (Co2+) affinity chromatography 
 
The yield of the pure protein was of 1 mg per litre of culture. For our purposes the level 
of protein purity gained with the metal affinity chromatography was sufficient and, 
considered the low yield of the protein expression, a further purification was not 
performed.  
 
~ 37 KDa 
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The metal affinity chromatogram consisted of different peaks corresponding to different 
steps of the elution by increasing concentrations of imidazole. Below I reported the 
SDS-PAGEs concerning the single step purification of PKA.  
 
 
Fig.16- SDS_PAGE of PKA after metal affinity chromatography 
 
 
 
 
10. Crystallization of hRARγS371E (LBD) in complex 
with 9-cis retinoic acid and X-ray crystal structure 
resolution  
 
10.1 Crystallization of hRARαS369E (LBD) in complex with 9-
cis retinoic acid and a coactivator peptide 
 
The ligand binding domain of hRARαS369E was expressed and purified. The protein 
bound to the agonist ligand 9-cis retinoic acid was concentrated up to 3, 6 or 8 mg/ml. 
The protein at a concentration of 6 mg/ml crystallized in presence of a SRC1 coactivator 
peptide. Crystals were tested and diffracted on a synchrotron source up to 2.7 Ǻ but 
resulted highly mosaic. Several attempts to optimize the crystallization conditions 
resulted unsuccessful.  
 
 
 
~ 40 KDa 
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10.2 hRARγS371E (LBD) in complex with 9-cis retinoic acid 
 
10.2.1 Preliminary crystallization trials  
 
The other protein isotype hRARγS37l E LBD was expressed and purified. The protein, 
bound to the ligand 9-cis retinoic acid, was concentrated up to 3, 6 or 8 mg/ml. 
Preliminary crystallization screenings were carried out using the sitting drop vapour 
diffusion method. Crystallization trials were performed in 1+1 µl, 96 wells Hampton 
Research Innovaplate crystallization plates. Screening around four hundred conditions 
resulted in three hits for crystallization condition optimization: the first is 0.2 M 
Magnesium nitrate hexahydrate and 20% Peg 3350, the second is 0.2 M Magnesium 
chloride, 0.1 M Tris HCl pH 8.0 and 20% Peg 6K and the third is 0.2 M Calcium 
chloride, 0.1 M Tris HCl pH 8.0 and 20% Peg 6K (Table 3) 
 
 
 
 
0.2 M Magnesium nitrate 
hexahydrate,  20% Peg 3350 
 
 
0.2 M Magnesium chloride, 
0.1 M Tris HCl pH 8.0, 20% 
Peg 6K 
 
 
0.2 M Calcium chloride, 0.1 
M Tris HCl pH 8.0, 20% Peg 
6K 
 
Table.3- Preliminary crystallization conditions and crystals 
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Crystals from these conditions appeared overnight at 17°C and kept growing over the 
next 3-4 days. The protein crystallizes in presence of the zwitterionic detergent 3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) and the neutral 
detergent n-dodecyl-β-d-maltopyranoside (C12M). Efforts to crystallize hRARγS371E 
in the absence of detergents and in presence of coactivator peptides were unsuccessful.  
 
 
10.2.2 Optimisation and scaling up of the crystallization conditions 
 
Optimisation screenings around the initial conditions were successfully performed by 
scaling up the size of the crystallization drops from 1 + 1 µl (protein+ reservoir) to 2 + 2 
µl using the hanging drop technique in Hampton Research VDX plates. 
This finer screening led to the growth of single crystals with improved visual quality.  
The best crystals were obtained from the following optimized conditions: 
 
(1) 0.3 M Magnesium nitrate hexahydrate, 18% Peg 3350 
(2) 0.2 M Magnesium chloride, 0.1 M Tris HCl pH 7.5, 14% Peg 6K 
(3) 0.3 M Magnesium chloride, 0.1 M Tris HCl pH 8.0, 14% Peg 6K 
(4) 0.2 M Calcium chloride, 0.1 M Tris HCl pH 7.5, 14% Peg 6K 
(5) 0.4 M Calcium chloride, 0.1 M Tris HCl pH 8.0, 14% Peg 6K 
 
Further improvements in the quality and size of the crystals were obtained on the basis 
of the optimized crystallization conditions by varying the ratio of protein and reservoir 
buffer constituting the drop as well as the volume of buffer in the reservoir. The best 
crystals were obtained from drops of 5 µl, constituted by a ratio 3: 2 of protein and 
reservoir buffer, and a reservoir volume of 1 ml. Single crystals appeared overnight at 
17°C and kept growing over one week to an average size of 200x200x100 µm3. All the 
optimized crystallization conditions produced bi-pyramidal crystals, very much similar 
in shape to the diffracting crystals obtained previously for hRARγ WT (LBD) for which 
the structure has already been solved92. 
 
One crystal grown in the condition with 0.2 M Calcium Chloride, 0.1 M, Tris HCl pH 
7.5, 14% Peg 6K with a size of 300x200x200 µm3 produced the best diffraction at a 
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resolution of 1.7 Ǻ.  Diffraction from this crystal produced clean and strong reflections. 
A total of 450 frames with 0.4 ° of oscillation angle were collected at the ESRF 
synchrotron BEAMLINE ID14-1 at 100 K. 
 
 
10.2.3 Data Processing, Molecular Replacement and Structure Refinement  
 
The data obtained for hRARγS371E (LBD) in complex with 9-cis retinoic acid were 
processed with the program HKL2000130. Results from data processing suggested the 
space group P41212 with one monomer per asymmetric unit and similar lattice 
parameters as for the hRARγ wild type LBD (PDB-ID: 3LBD92). Following data 
processing, molecular replacement was carried out to find the solutions for the new 
complex using the hRARγ wild type LBD structure as a starting model. This calculation 
was done by using AMoRe125integrated in the graphical interfaced version of the CCP4 
(Collaborative Computational Project, 1994). A unique solution was obtained and 
refinement of the structure was started with the rigid body. Manual building of the 
structure was carried out with COOT52 with iterative cycles of structure refinement 
performed through REFMAC5123. The parameters and the topology coordinates for the 
ligand and the detergent were generated from PRODRG156 as REFMAC5 uses 
PRODRG files. The final steps of the refinement included the addition of the ligand, the 
detergent and the water molecules. The final structure reported values for Rwork and Rfree 
that were respectively of 19.4% and 23.4%. Refer to table 4 for an overview of data 
collection parameters and refinement statistics. Ramachandran plot for the geometry of 
the main chain is shown in Figure 17.  
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hRARγS371E (LBD) in complex with 9-cis retinoic acid 
Data processing  
Resolution (Å) 50-1.69 (1.72-1.69) 
Crystal space group  P41212 
Cell parameters (Å) = b = 59.9, c = 157.4 
Unique reflections 32495 (1589) 
Mean redundancy 13.4 (12.3) 
Rsym (%)a 4.4 (31.8) 
Completeness (%) 100 (99) 
Mean I/σ 70.17 (11.81) 
Wilson B factor (Å2) 22.1 
Refinement  
Resolution (Å) 50-1.69 
Number of non-hydrogen atoms  
  RAR-LBD 1852 
  Ligands 22  
  Water molecules 157 
RMSD bond length (Å) 0.01 
RMSD bond angles (˚) 1.11 
Rcryst (%)b 19.4 
Rfree (%)c 23.4 
Ramachandran plot (%)  
  Core 94.2 
  Allow 5.8 
  Generous 0 
 
Table 4. Data collection and refinement statistics 
 
a
 Rsym = 100 × Σhj |Ihj – <Ih>| / Σhj Ihj, where Ihj is the jth measurement of the intensity of reflection h and <Ih> is its 
mean value. 
b
 Rcryst = 100 × Σ||Fo| – |Fc|| / Σ|Fo|, where |Fo| and |Fc| are the observed and calculated structure factor amplitudes, 
respectively. 
c
 Calculated using a random set containing 5% of observations that were not included throughout refinement 
[Brünger A. T., (1992) The Free R Value: a Novel Statistical Quantity for Assessing the Accuracy of Crystal 
Structures, Nature 355, 472-474]. 
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Fig.17- Ramachandran plot of the structure of hRARγS371E (LBD) in complex with 9-cis 
retinoic acid 
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11. Molecular dynamics studies of the effects of the    
S371 phosphorylation onto RARγ 
Molecular dynamics studies have been carried out in collaboration with Dr. Annick 
Dejaegere’s group.  These studies aimed at the investigation of the effects of the 
phosphorylation of the serine located into helix H9 of the RARγ LBD with particular 
regard to the effects of this phosphorylation onto hCycH binding region. Molecular 
dynamics simulations have been carried out onto hRARγ WT (LBD) and its mutant, 
hRARγ S371E, on the basis of the respective crystal structures. The structures of 
phosphorylated mutants of hRARγ S371 carrying respectively one (S371P1) or two 
(S371P2) negative charges were built and analysed. Mutants of hRARγ S371E in which 
the glutamic acid was substituted by a phosphorylated serine residue carrying 
respectively one (RAR-mut- pho 1) or two (RAR-mut- pho 2) negative charges were 
also built and analysed. 
 
11.1 Structures preparation for molecular simulation 
Force fields to describe the nuclear receptors LBDs, the 9-cis retinoic acid and the 
hydrogen atoms were introduced29, 111, 112. The protonation state of the residues, 
determining the total charge of the protein and the local distribution of the charges 
around the amino acids, was established on the basis of two different programs 
PROPKA and UHBD12, 108, 154, 173.   
The dynamics were produced with the program NAMD135. The hydrogen bonds were 
fixed with the algorithm SHAKE to improve calculation times153. The temperatures 
were adjusted at each step and the pressure was constantly controlled with a Langevin 
piston. 
To delete the wrong contacts between the protein and the solvation water molecules, an 
energy minimisation of 1000 steps with conjugated gradient (CG) was carried out. 
 69 
During this step the protein, the ligand and the water molecules were fixed.  Then the 
system was warmed up to 600°K for 23 steps. A shorter energy minimisation (CG) was 
carried out followed by a warming up step to 300°K. In a second moment the protein, 
the ligand and the crystallographic waters were not kept fixed anymore and an energy 
minimisation (CG) of 2000 steps was carried out, followed by a warming up of 13 steps 
up to 300°K. An equilibration step was then followed by the observation time during 
which the conformations of the structure was investigated.  The dynamics of each 
system was studied in isotherm and isobar conditions for a total of 6800 hours of 
calculations on 512 processors.  
 
11.2 Analysis 
11.2.1 RMSD 
The Root Mean Square Deviation (RMSD) value provides a description of the 
differences in the structure of the protein at a given time of the simulation to respect to 
the initial protein structure taken as reference. The structures of the protein at different 
times were superimposed to the structure of the reference protein and the corresponding 
RMSD value calculated according to the formula: 
 
                                
where N represents the number of atoms for which the RMSD is calculated and di 
represents the distance between the coordinates of the atom i in the two superposed 
structures. 
 
RMSD  
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11.2.2 Fluctuations RMS 
This value provides an estimation of the mobility of a structure at a given time of the 
simulation to respect to the averages structure. The average structure out of all the 
possible conformations is calculated on the basis of the average position < ri > of each 
atom. 
 
 
11.2.3 Hydrogen bonds analysis 
Interactions between an acceptor and a donor atom were considered as hydrogen bonds 
within 3.4 Ǻ. The number and the life time of the hydrogen bonds originated during the 
simulations were analysed for each system with the program Multivac (M. Ferrario, G. 
Marchetti, M. Oberlin, A.  Dejaegere, not published). 
 
11.2.4 Dihedral angles analysis 
The dihedral angle adopted by the protein backbone and by each residue during the 
dynamic simulation was analysed wit the program Multivac (M. Ferrario, G. Marchetti, 
M. Oberlin, A.  Dejaegere, not published). 
.  
 
 
Fluctuations RMS of the atom i 
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12. Dynamic studies of the RARα wild type and 
RARαS371E by nuclear magnetic resonance (NMR). 
 
12.1 Preliminary 2D heteronuclear spectra 
 
Preliminary heteronuclear 2D experiments were carried out onto 15N-hRARαS369E and 
15N-hRARαWT in complex with the ligand 9-cis retinoic acid. The alpha isotype of 
RAR was used in these experiments due to the lack of monodispersity of the RARγ 
isotype in NMR suitable buffer conditions. The samples were placed in a 3mm NMR 
tube and spectra were acquired on a Bruker Avance 800 MHz spectrometer.  
The HSQC spectra were registered at different temperatures, pH and buffer 
compositions to find the optimal conditions for the acquisitions.  
Difference of probe temperature between 298K and 303 K did not affect significantly 
the spectra while a decreasing value of the pH from 7.5 to 6.5 increased the spectra 
quality as at pH 6.5 a considerable number of missing signals were recovered.  
The best condition for spectra acquisition resulted to be common to the two proteins and 
is described here below: 
 
 
Buffer composition            Bis-Tris10NaCl300Chaps1.5 TCEP1 (mM) pH 6.5 
Protein concentration         ≈ 400µM 
T probe                303 K 
 
 
 
1H-15N HSQC spectra of 15N-hRARαS369E and 15N-hRARαWT were acquired in the 
previously described conditions and the spectra were superimposed. Significant shifts 
for several peaks are enlightened in the black boxes (Fig. 18) 
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Fig.18-   1H-15N HSQC spectra of 15N-hRARαS369E and 15N-hRARαWT acquired on a  
   Bruker Avance 800 MHz spectrometer, at 303K. 
 
 
 
12.2 RARα wild type and RARαS371E 15N longitudinal and 
transverse longitudinal relaxation rates measurements 
 
 
Protein backbone 15N spin relaxation rates can be measured by solution NMR and 
provide useful dynamic information with a residue-specific resolution. In a 15N 
relaxation experiment, one creates non-equilibrium spin order and records how this 
relaxes back to equilibrium. At equilibrium, the 15N magnetization is aligned along the 
external field. This alignment can be altered by radio frequency pulses. The 
magnetization will relax back to equilibrium along the direction of the magnetic field 
with longitudinal relaxation rate R1.  
1H 
RARα S369E  
RARα Wild type  
1H (ppm) 
15 N 
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Outside the equilibrium the magnetization also has a component perpendicular to the 
external magnetic field. The constant rate for this spin component to return to 
equilibrium is called transverse relaxation rate R2. The conventional method to perform 
relaxation rates measurements is to record a series of 2D 1H-15N HSQC spectra with 
varied relaxation delays and derive 15N relaxation rates by numerical fitting of the 
relaxation free induction decay data (FID).  
In order to highlight differences in the dynamics of wild type RAR and its mutant 
relaxation experiments were performed on Avance Bruker 500 MHz spectrometer at 
298K onto samples of 15N-hRARαS369E and 15N-hRARαWT in complex with the 
ligand 9-cis retinoic acid. Both the protein samples were prepared in previously found 
optimised conditions and had a final concentration of about 300 µM.              
15N longitudinal relaxation rate R1, traverse relaxation rate R2, and steady-state 
heteronuclear NOEs, were measured with pulse sequences described by Farrow et al. 54. 
R2 were measured using a refocusing time of 450 ms. In all experiments the water 
signal was suppressed with ‘water flip-back’ scheme .The 15N longitudinal relaxation 
rates, R1, were measured using delays in the pulse sequence of 2.5, 35, 75, 125, 250, 
500, 750,1000, 2000 and 3000 ms for both the protein samples. The relaxation delays 
used for 15N transverse relaxation rates R2 were of 16.96, 33.92, 50.88, 67.84, 84.8, 
118.72, 169.6, 220.48, 288.32 ms for both the protein samples. 
The heteronuclear 1H-15N NOEs were calculated considering the ratio of the peak 
volumes in spectra recorded with and without 1H saturation.  Each experiment was 
comprised of 32 scans for R1 and R2 experiments and 64 scans for 1H-15N NOE 
experiments. All 2D data consisted of 2K data points in the acquisition dimension and 
of 256 experiments in the indirect dimension. 
Relaxation rates R1 and R2 were determined by fitting the cross-peak intensities (I) as a 
function of the delay (t) within the pulse sequence, to a single exponential decay curve 
according to the following equation (Fig.19) : 
 
I(t) = A·exp[-R· t] 
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where A, and R were adjustable fitting parameters. The value for the correlation time τc 
was estimated from the R2 and R1 ratio and resulted of 17ns. 
 
Fig.19- Intensity decay vs. time delay between two consecutive pulse sequences plotted for 
peak   number 130. 
 
 
 
 
 
 
I 
t[ms] 
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Chapter 4 : Results and Discussion 
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13. X-ray crystal structure of hRARγS371E (LBD)  
 
13.1 X-ray crystal structure of hRARγS371E (LBD) in complex 
with 9-cis retinoic acid 
 
Phosphorylation at the RARγ ligand binding domain (AF-2) by PKA enhances the 
binding of hCyclinH to the receptor and therefore facilitates the phosphorylation of 
RARγ (AF-1) domain by CAK24.  
We investigated the consequences of the phosphorylation on the structure of RARγ 
ligand binding domain by comparing the high resolution crystal structures of the 
RARγ WT (LBD) with that of the S371E mutant in which the mutation reproduces in 
large part the effects of a phosphorylation event.  
 
The ligand binding domain of hRARγS371E bound to the ligand 9-cis retinoic acid was 
crystallized in presence of the neutral detergent n-dodecyl-β-d-maltopyranoside (C12M), 
required for stabilization of hRARγS371E (LBD)91. Optimized crystals were tested on a 
synchrotron source and a complete data set was collected at 1.7 Ǻ. Crystals belong to 
the tetragonal space group P41212 with one monomer per asymmetric unit. The structure 
was solved by molecular replacement using hRARγ WT as a starting model92.  
After refinement the reported values for Rfactor and Rfree were respectively of 19.4% and 
23.4%. The human RARγS371E-holo-LBD adopts a classical anti-parallel alpha helical 
"sandwich" (Fig.20) similar to that of the wild type RARγ LBD structure conformation 
firstly described for hRARγ146. The electron density map showed the presence of the 
ligand buried into the ligand binding pocket and an extra electron density around 
position 371 confirmed the mutation of the serine residue into a glutamic acid. The 
detergent mediates a crystal contact in the region of the receptor involved in coactivator 
binding. The dodecyl moiety of the detergent is buried in a hydrophobic channel, 
whereas the maltoside head group establishes a hydrogen bond with water molecules 
and polar residue side of the chains. 
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Fig.20- X-ray Crystal structure of hRARγS371E in complex with 9-cis retinoic acid. The 
ligand, buried in the ligand binding pocket, is in blue; the detergent C12M is in purple.                               
 
The hRARγS371E (LBD) and hRARγ (LBD) structures are isomorphous (respectively 
in green and blue in Fig 21). The r.m.s. deviation calculated on the carbons alpha of the 
backbone is of 0.47 Ǻ. Interestingly one of the two highest r.m.s.d values, equal to 1Ǻ, 
is localised in the loop 8-9 involved in cycH recognition and binding rather then in the 
mutation region (Fig. 22). 
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Fig. 21– Superposition of the crystal structures of the LBDs of hRARγWT (blue) and 
hRARγS371E (green), in complex with the agonist ligand 9-cis retinoic acid (light blue).  
In pink the detergent C12M. The two structures are isomorphous. 
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Fig.22– Two regions in RARγS371E display r.m.s.d values of 1Ǻ (in red). One of these 
regions belongs to the part of RARγS371E involved in the hCycH docking (circled). In blue the 
mutation S371E.   
 
 
 
 
 
 
S371E 
 S371E 
CycH 
docking site 
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The analysis of the three-dimensional structures of hRARγWT and the mutant 
hRARγS371E showed a very similar orientation of the side chains. Remarkably a 
significant difference in the orientation of the side chains involves the loop 8-9 
responsible for the hCycH binding. More precisely this difference is located at the level 
of the residue ASP340. In hRARγS371E this residue forms a salt bridge with ARG387 
belonging to H10 (Fig.23). This salt bridge is not formed in the hRARγWT due to the 
orientation of the ARG387 which now points toward the solvent. Moreover in the 
transcriptional active heterodimer formed by hRARβ and RXRα in complex with 9-cis 
retinoic acid, the ARG residue (ARG378 in RARβ) is implicated in a salt bridge with 
other residues belonging to RXR and adopts an orientation that resembles that of the 
WT rather then that of the mutant137.  
 
 
 
Fig. 23– Superposition of hRARγS371E and hRARγWT crystal structures. In 
RARγS371E (in red) a salt bridge involves ASP340 (loop 8-9) and ARG387 (H10). This 
salt bridge is not present in RARγWT (in green).  
  
 
ARG387 
ASP340 
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14. Molecular dynamics studies on hRARγS371E (LBD) 
 
Molecular dynamics studies of the ligand binding domain of hRARγ WT and its 
mutants were performed in collaboration with Dr. Dejaegere’s team and aimed at 
contributing to the understanding of the effects of the phosphorylation of the RAR 
ligand binding domain onto the region of the receptor involved in the recruitment of 
hCycH.  
   
 
14.1 Molecular dynamics studies onto RARγ 
 
Μolecular dynamic simulations enlightened that the phosphorylation region of RAR 
and the region involved in the recruitment of hCyhH, both rich in charged amino acids, 
possess peculiar electrostatic characteristics. In particular the two methods used for the 
calculation of the protonation state of RAR residues, PROPKA and UHBD provided 
contradictory results for few amino acids: ASP324, GLU327 could be neutral and the 
CYS338 could be charged. Interestingly the ambiguous residues are located respectively 
in spatial proximity of the phosphorylation site (ASP324, GLU327) or of the CycH 
binding site, loop 8-9 (CYS338).  Two protonation states were tested and the distances 
between the residues having an ambiguous degree of protonation were measured during 
the dynamic simulation.  Significantly none of the tested conditions reproduces exactly 
the whole set of the crystallographic distances indicating the existence of multiple 
possible conformations corresponding to different protonation states of the residues.  
 
Hydrogen bond formation was analysed during the dynamic symulation as any stable 
modification of the life time of a hydrogen bond can be part of a regulation mechanism. 
Hydrogen bonds modifications were monitored in the region close to RAR 
phosphorylation site and to hCyc binding site. Alternative hydrogen bonds in the RAR 
phosphorylation site can originate depending on the protonation state of the residues 
located in proximity of S371 and on the modifications occurring on S371. Interestingly 
formation of alternative hydrogen bonds in the phosphorylation site and involving 
residues located in the loop 8-9 were observed for any of the tested protonation states. 
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The existence of a salt bridge between the conserved ARG387, located in H10, and 
ASP340 belonging to the CycH binding region comprising loop 8-9 was observed in 
hRARγS371E but not in hRARγWT. When the S371 residue is phosphorylated the 
formation of the salt bridge between ARG387 and ASP340 arises spontaneously and 
rapidly. When the simulation is carried out onto hRARγS371E the existing salt bridge 
between ARG387 and ASP340 is unmodified during in the dynamics. Molecular 
dynamics onto hRARγWT showed, on the contrary, that the formation of the salt bridge 
between ARG387 and ASP340 is transient during the simulation. These results 
demonstrated for the first time the existence of a dynamic coupling between the regions 
involved in PKA phosphorylation and that involved in the recognition of hCycH.  
 
 
15. NMR 
 
15.1 NMR studies of hRARαS371E (LBD) and of hRARα WT 
(LBD) in solution 
 
High resolution three-dimensional structure of proteins can be solved either in solid 
state through X-ray crystallography, or in solution through NMR spectroscopy. NMR 
has the advantage of studying proteins under conditions as close as possible to their 
physiological state. 
NMR spectroscopy provides information ranging from the protein folding to the internal 
motions of the protein. All these aspects are essential for a deep understanding of the 
protein biological functions.  
 
 
NMR structural studies of hRARαS371E LBD and hRARα LBD in solution required 
the isotopic enrichment of the proteins with 15N. HSQC (heteronuclear single quantum 
correlation) experiments were carried out on both proteins.  
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The HSQC experiment is the most important inverse NMR experiment. In a HSQC the 
nitrogen atom of an NHx group is directly correlated with the attached proton. In the 
resulting spectrum each HSQC signal represents a HN proton of the protein backbone 
and, since there is only one backbone HN per amino acid, each cross-peak corresponds 
to one single amino acid. 
1H-15N HSQC spectra for 15N-hRARαS369E and 15N-hRARαWT were performed in 
previously optimised and common conditions. The HSQC spectra of both the proteins 
showed well dispersed resonances that suggest the proper folding of the protein.  
Superposition of 1H-15N HSQC spectra of 15N-hRARαS369E and 15N-hRARαWT 
enlightened significant shifts in the resonances of several residues as showed (Fig.18, 
black boxes) but identifying the shifting residues requires the assignment of the protein 
backbone.  
 
 
Measurements of l5N relaxation rates of the proteins were used for obtaining 
information about the dynamics of hRARαS369E and hRARαWT in solution. 
Spin relaxation comprises a series of processes leading magnetization to decay over 
time and is composed by two components: T1 and T2 (commonly we refer to the 
inverse of the T1 and T2 as the relaxation constant rates, R1 and R2 respectively). T1 is 
the longitudinal relaxation time and it corresponds to the restoration of equilibrium 
between the numbers of nuclei in the high and low energy spin states. T2 represents the 
time needed to re-gain phase coherence of the spins. 
Specific pulse sequences gather structural information by transferring magnetization 
from one nucleus to another and allowing magnetization to evolve over time. 15N 
relaxation time is physically correlated to the overall rotational correlation time of the 
protein (tumbling rate), as well as to the internal flexibility of the polypeptide chain. 
The most important factor influencing T2 is the tumbling rate of the protein which is a 
function of the size of the protein. Protein tumbling generates oscillating magnetic 
fields. Slow tumbling generates fields in the right frequency range to interact with the 
fields generated by the magnetic nuclei allowing an exchange of energy and fast 
relaxation times. On the contrary, fast tumbling determine long T2. Because relaxation 
time has to be long enough to allow the recovery of a useful signal, nuclear magnetic 
resonance is limited to the study of small molecules. Relaxation measurements 
performed onto the 15N-hRARαS369E and 15N-hRARαWT enlightened that the large 
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majority of the analyzed residues feature very similar relaxation rates except for ten 
residues in the hRARαS369E which have higher longitudinal rates with respect to the 
hRARαWT. This result indicates residue-specific differences in the dynamics of the 
two proteins. Relaxation rates are consistent with a protein in a monomeric state 
possessing a correlation time of 17 ns.               
 
 
16. Conclusions and Perspectives 
 
Recent studies highlighted that nuclear receptors (NRs) mediated transcription is 
regulated not only by the ligand binding but also through post-translational modification 
events such as phosphorylation. Deregulation of receptor phosphorylation leads to 
several types of cancers such as breast, ovarian and prostate cancer but up to date 
nothing is known about NR regulation through phosphorylation and no structure of 
phosphorylated nuclear receptor is available. 
The human retinoic acid receptor gamma (hRARγ) belongs to the NR superfamily and 
is phosphorylated at the N-terminal domain by the TFIIH associated form of CAK and 
at the ligand binding domain by the cyclic AMP-dependent protein kinase (cAMP-
PKA). Phosphorylation at the ligand binding domain by PKA enhances the binding of 
Cyclin H, a subunit of the CAK, to the receptor and therefore facilitates the 
phosphorylation of hRARγ domain by CAK and the transcription of cognate target 
genes. We aimed at providing new structural insights to understand at atomic level the 
impact of PKA phosphorylation at RAR ligand binding domain on the structure of RAR 
LBD. 
We expressed, purified and crystallized the ligand binding domain of hRARγS371E in 
which the mutation is well known to mimic a phosphorylation event. The X-ray crystal 
structure of hRARγS371E (LBD) was solved at 1.7 Ǻ. Superposition of hRARγS371E 
(LBD) and hRARγ WT (LBD) crystal structures enlightened that the two structures are 
isomorphous with an r.m.s.d value, calculated onto the carbon alphas of the backbone, 
of 0.47 Ǻ. Our X-ray crystallography structure details enlightened structural differences 
between RAR wild type and mutant, located at the level of the CycH docking site. 
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Analysis of the r.m.s.d values showed that one of the two regions displaying higher 
r.m.s.d values involves residues from 340 to 343, located in the region of receptor that is 
responsible for the recognition and binding of CycH (loop 8-9).  A remarkable 
difference in the orientation of the side chains also involves the region of the receptor 
responsible for CycH binding. This difference is located at the level of the residue 
ASP340 which in hRARγS371E, but not in RARγWT, forms a salt bridge with ARG387 
(H10).  Our results demonstrated that the effects of the phosphorylation on the residue 
SER371 of RAR, mimed by the mutation S371E, do not affect profoundously the 
structure of RAR but they could finely tune the structural dynamics of the receptor.  Our 
hypothesis were confirmed by molecular dynamic simulations, performed on the basis 
of the crystal structures of the wild type and mutant receptor, which highlighted for the 
first time a dynamic interaction between the mutation region of RAR and the CycH 
docking site.  
To understand whether the mutation at S371 of RARγ is responsible for the structural 
modifications localized at the CycH binding site of the receptor we performed NMR 
mobility studies on both RAR WT and mutant. 
Differences in the dynamics of wild type RAR and its mutant were pointed out through 
15N longitudinal and traverse relaxation rates measurements performed onto the 15N 
isotopically enriched proteins. The large majority of the analyzed residues featured very 
similar relaxation rates when comparing hRARα wild type to the mutant but a few 
residues in hRARα mutant showed higher longitudinal relaxation rates with respect to 
the wild type. To analyze in greater details the difference in mobility between RAR 
wild type and its mutant protein backbone assignment is required.  The power of NMR 
results from the fact that the overlapping signals originated by biological 
macromolecules can be resolved by multi-dimensional NMR techniques. This becomes 
more difficult for larger macromolecules (more than 30 KDa) and establishes a limit to 
the molecular size of the molecules that can be studies by NMR. In these cases protein 
samples enriched with NMR active isotopes l5N, l3C, 2H are required.                                                                               
RAR molecular weight is approximately of 28KDa. Therefore a more detailed analysis 
of the difference in mobility between RARα wild type and its mutant, which needs 
spectra assignment of the protein backbone, will most probably require the production 
of protein samples enriched with 2H/I3C/I5N isotopes.  
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17. Biophysical characterization of the interaction between 
hCycH and hRARα  
 
 
17.1 Surface Plasmonic Resonance (SPR) 
 
 
 
Surface Plasmonic Resonance experiments were initially performed to study the 
interaction between hCycH and hRARα and monitor the effects of the mutation S369E 
on the binding. 
The hRARα, hRARαS369E, hRXRα ligand binding domains were purified in presence 
of the ligand 9-cis retinoic acid and immobilized onto a four channel biacore chip by 
means of the GST fusion tag. 
Either RXRα or pure GST should not provide any specific interaction with hCycH and 
were therefore taken as negative controls.  
The LBD domains were stably captured on the chip as confirmed by the rapid 
association and dissociation kinetics. A concentrated sample of hCycH (115µM) was 
then passed over the four channels at the same time.  
Considering the GST signal as baseline, a positive signal of 15 RU (1 RU, Response 
Unit, corresponds to 1pg mm-2 of bound protein) was measured for the interaction 
between RARS369E (LBD) and hCycH, corresponding to a binding affinity in the µM 
range. No specific signal was detected, instead, for the interaction between hRARα or 
RXRα and hCycH, as shown by the binding profiles (Fig.24)  
In later experiments an hCycH concentration-dependent signal confirmed the specificity 
of hCycH-hRARαS369E interaction (Fig. 25). 
SPR results were consistent with our predictions and indicated that hCycH interacts 
specifically with hRARαS369E but not with hRARα or hRXRα. 
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Fig. 25- Immobilized GST- hRARαS369E (yellow), hRARαWT (purple), hRXRα (blue), LBDs 
titrated with  increasing concentration of hCycH (0-60 µM) 
 
[CycH mg/ml] 
RU 
Fig. 24- (a) Binding profiles of the interaction between the immobilized hRARαS369E 
(purple), hRARαWT (blue), hRXRα (green), LBDs or GST (red) and hCycH (115µM). In   
(b) a zoom of the plateau region. 
 
(a) 
(b) 
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17.2 Preliminary study of the interaction of RARα with PKA 
through NMR 
 
 
The RARα WT (LBD) was incubated with the phosphorylation buffer containing ATP 
and Mg2+ at pH 6.5. A 1H-15N HSQC was acquired on a Bruker Avance 800 MHz 
spectrometer, at 303K. (Fig.26, red peaks) 
The protein sample was subsequently incubated in presence of PKA kinase and 
phosphorylation of RARα at position S369 was checked by immunoprecipitation. 1H-
15N HSQC spectra were acquired on the phosphorylated RARα WT (Fig.26, blue 
peaks). 
Upon addition of PKA to the sample, we enlightened chemical shift variations for 
several residues (Fig.26, black boxes and Fig.27).  
Identification of the residues resonating at different values of the chemical shift will 
need protein backbone assignment. 
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Fig.25- Superposition of 1H-15N HSQC spectra of RARαWT (in red) and RARαWT after 
incubation with PKA (in blu). The spectra were acquired on a Bruker Avance 800 MHz 
spectrometer, at 303K. 
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(a) 
 
(b) 
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(c) 
 
Fig-26 – (a), (b), (c): Different regions of the 1H-15N HSQC spectra showing the superposition 
between RARαWT (in red) and RARαWT after incubation with PKA (in blue). The three 
images enlighten chemical shift variations for several residues. 
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18. Materials 
 
18.1 Molecular biology 
 
18.1.1 Plasmid Amplification and Purification: DNA Mini Prep 
 
The purification of the plasmids was performed with “NucleoSpin plasmid” kit from 
Macherey-Nagel. E. coli (DH5α) cells were transformed with the plasmids containing 
the genes of interest and 5 ml over-night cultures were set up. Cells from these cultures 
were collected by centrifugation and resuspended in 250 µl buffer A1. Two hundred 
fifty µl buffer A2 was added inverting the tube four times and the suspension incubated 
at room temperature for 5 min. Three hundred µl buffer A3 was added gently inverting 
the tube four times. The suspension was centrifuged at 11000 rpm for 10 min. The 
supernatant was transferred into the NucleoSpin plasmid column and centrifuged for 1 
min at 11000 rpm. The column was washed with 600 µl buffer A4 and centrifuged at 
11000 rpm for 1 min. The flowthrough was discarded and the membrane dried up by 
centrifuging for 2 min at 11000 rpm. Fifty µl sterile H2O was added and the plasmid 
eluted by centrifugation at 11000 rpm for 1 min. 
 
 
18.1.2 LR-Gateway reactions 
 
Gateway Technology provides a high throughput technology to transfer simultaneously 
the gene of interest into different cloning vectors. The Gateway cloning technology is 
based onto a two step reaction. In the first step (BP reaction) the gene of interest, 
amplified with primers flanked by attB sites, recombines with a donor vector containing 
attP sites. The resulting entry vector contains the gene of interest flanked by attL sites 
and possesses resistance to the antibiotic kanamicine. In the second step (LR reaction) 
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the entry vector is mixed with the destination vector containing attR sites. 
Recombination between attL and attR sites occurs in presence of Gateway clonase 
enzyme and generates the expression vector containing the gene of interest and 
resistance to ampicilline (Invitrogen, Gateway Technology Manual, 2003). 
 
Starting from pDON207 entry vectors containing respectively hRARα, 
hRARαS369E and hRXRα (LBDs) genes, LR recombination reactions were performed 
in presence of pGex-4T3-Gateway destination plasmid. One µl from each LR reaction 
was transformed in E. coli DH5α cells and positive clones were selected onto solid 
medium in presence of antibiotic.  
One colony from each transformation was transferred into 100 µl LB in presence of 
antibiotic and incubated for 3h at 37° C under constant agitation. One and a half µl of 
the respective precultures was used to test the efficiency of the LR reactions by PCR.   
 
18.1.3 Polymerase chain reaction (PCR)  
 
18.1.3.1 Point mutation at position 369 of RARα and position 371 of RARγ 
(LBDs)  
 
In vitro site-directed mutagenesis at position 369 of RARα LBD, exchanging a serine 
with a glutamic acid, was carried out in a single PCR step. The pDon207 vector 
containing the gene of RARα LBD was used as a template and the following set of 
primers: 
 
5’- CGGAAGCGGAGGCCCGAACGCCCCCACATGTTC  
5’- GAACATGTGGGGGCGTTCGGGCCTCCGCTTCCG  
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were respectively used as forward and reverse primers. Table 5 describes the 
composition of one PCR reaction. 
 
Reagent  Volume (µl) 
Plasmid DNA (17 ng/µl) 0.6 
Polymerase buffer HF (5x) 5 
dNTP (2mM each) 10 
Forward primer UP1 (100 nM) 3 
Reverse primer GWR (100 nM) 3 
DMSO 5 
H2O Up to 49 
PFU Polymerase  1 
Table 5- Composition of one PCR reaction  
 
The PCR program that was used is reported below: 
30 sec  at                  98° C 
 
7 sec  at                  98° C 
20 sec  at                  55° C 
15sec/Kb at          72° C 
 
7 min  at                  72° C 
 
 
Sequence analysis of the resulting plasmid was performed to ensure that the desired 
mutation was successfully introduced.  
30 Cycles  
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18.1.3.2 Determination of the efficiency of the LR reaction 
 
Polymerase chain reaction (PCR) was carried out to test the efficiency of the LR 
Gateway cloning step of RARα, RARαS369E and RXRα (LBDs) genes into pGex-
4T3-Gateway expression vectors.   
The reagents listed in table 6 were mixed to perform one PCR reaction. 
Reagent Volume (µl) 
Preculture 1.5 
Polymerase buffer 10x 2 
dNTP (2mM each) 2 
Forward primer SP136 (10 µM) 1 
Reverse primer GWR (10 µM) 1 
H2O Up to 19.5 
Taq Polymerase  0.5 
Table 6- Composition of one PCR reaction  
 
The PCR reaction was carried out according to the program below and two µl of the 
reaction were analysed by agarose gel electrophoresis.  
 
4 min  at                  94° C 
 
1 min  at                  94° C 
45 sec  at                  55° C 
1 min/Kbp at            72° C 
 
5 min  at                  72° C 
30 Cycles  
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18.2 Protein Expression 
 
18.2.1 Cell Transformation 
 
A hundred ng of the expression vector was transformed into 50 µl of thermo competent 
E. coli BL21 (DE3) cells for protein expression or DH5α  for plasmid purification. The 
cells were incubated on ice for 30 min and then osmotic shock was carried out for 90 
seconds at 42°C, followed by incubation on ice for 2 min. Two hundred 200 µl LB-
medium was added and the cells incubated at 37°C for 1 hour under constant shacking 
at 250 rpm. 
The cells containing the gene of interest were selected onto LB-agar plates in presence 
of the correspondent antibiotic. Thirty or eighty µl of cell suspension was plated out 
respectively from BL21 (DE3) or DH5α transformations in order to obtain isolated 
colonies. The plates were incubated overnight at 37°C. 
 
18.2.2 Small Scale Protein Expression Tests 
One single colony from the LB-agar plate was inoculated in 5 ml of LB-medium in 
presence of antibiotic and incubated at 37°C overnight shaking at 250 rpm. Twenty-five 
ml LB-medium containing antibiotic were inoculated with of the overnight culture to 
have a starting OD600 of 0.15. The culture was incubated at 37°C shaking at 250 rpm till 
OD600 value reached 0.6. Protein expression was induced with 0.8 mM IPTG 
(Isopropyl-beta-thio-galactoside). The cultures were incubated for four hours at 25° C 
shaking at 250 rpm. Five hundreds µl of culture was collected before induction, as a 
negative control for protein over-expression. The cells from this aliquot were collected, 
resuspended in 100 µl 2x Laemli buffer and heated to 100° C for 10 min. Ten µl was 
loaded on the 15% SDS-page.  
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18.2.3 Small Scale Protein Purification Test 
 
Cells from the 25 ml culture were collected by centrifugation at 4000 rpm for 10 
minutes. The cell pellet was resuspended in 1.5 ml lysis buffer (T20mM, NaCl500
 
mM) 
and 150 µl Lysozime (25 mg/ml) was added. The pellet was homogenized and the 
suspension incubated on ice for 15 min and put at 37° C for 5 min. Sonication was 
carried out 3 times for 30 seconds at 1 min intervals with a 3 mm tip sonicator at 
amplitude of 20%. The suspension was centrifuged for10 min at 14000 rpm and the 
supernatant recovered. 
 
Fourty µl Talon or Nickel Sepharose metal chelating resin or 30 µl Glutathione 
Sepharose 4B resin was washed with deionised water. The suspension was centrifuged 
at 1000 rpm for 2 min and the beads equilibrated with 200 µl lysis buffer for four times. 
At each step the supernatant was discarded upon centrifugation. The clarified lysate was 
added to the resin and incubated respectively for 30 min (Talon or Nickel Sepharose) 
and 1 hour (Glutathione Agarose). The resin was collected by centrifugation at 1000 
rpm for 2 min and washed 5 times with 200 µl of lysis buffer, the supernatant discarded. 
For His-tagged hRARs, hRXR, hCycH and PKA 50 µl elution buffer (T20mM, 
NaCl500
 
mM, Imidazole 1M) were added to the resin, the resin centrifuged at 1000 rpm 
for 2 min and the supernatant collected. Three µl of the eluted protein was mixed with 6 
µl 2x Laemli buffer and loaded on SDS-PAGE. For GST-tagged hRARs and hRXR, 
100 µl 2x Laemli buffer was added to the resin and incubated at 100° C for 10 min. The 
resin was spun down by centrifugation and three µl of the suspension was loaded on 
15% SDS-PAGE.  
 
18.2.4 Over-night Precultures 
 
One single colony was added to 500 ml pre-autoclaved LB-medium in presence of the 
required antibiotic. The culture was incubated over-night at 37° C shaking at 200 rpm.  
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18.2.5 Large Volume Cultures 
 
The components for one litre of LB-Home were dissolved in 800 ml of water in a 5 liter 
Erlenmeyer flask and autoclaved. Sterile sucrose was successively added up to one litre. 
The adapted volume of overnight preculture was added in presence of antibiotics to the 
1 litre culture in order to obtain an initial value of OD600 of 0.15.  The culture was 
incubated at 37° C and shacked at 250 rpm until OD 600 reached the value of 0.6. Protein 
expression was induced with 0.8 mM IPTG and culture incubated at 25° C for four 
hours. Cells were harvested by centrifugation, at 4000 rpm for 20 min. Pellet was 
resuspended in 25 ml fresh LB and centrifuged for 20 min at 4000 rpm. The supernatant 
was discarded and the pellet stored at -20° C.  
 
18.2.6 Large Volume Cultures Isotopically Enriched With 15N 
 
The chemically defined minimal medium M9, isotopically enriched with the isotope 
15N, was used to express 15N labelled hRARα and hRARαS369E. Five hundred ml of 
minimal media was prepared in a 5 liter Erlenmeyer flask, added with the required 
antibiotic. The volume of overnight preculture was added in order to obtain an initial 
value of OD600 of 0.15. For the composition of the M9 minimal media see Table 7. 
 
 
Chemical  1 Litre Culture 
M9 5X – NH4 200 ml 
Glucose 20% 20 ml 
(15NH4)2SO4 1.25 g 
MgSO4 1M 2 ml 
CaCl2 1M 100 µl 
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FeSO4 3.5 mM 100 µl 
Thiamine 10 mg/ml  1 ml 
Biotine 10 mg/ml 1 ml 
Vitamines T.t 1 ml 
H2O Up to 1 litre 
 
M9 5X Solution 1 Litre Culture 
Na2HPO4(H20)12 85g 
KH2PO4 15g 
NaCl 2.5g 
Table 7- Composition of media 
 
 
18.3 Protein Purification  
 
18.3.1 Sonication and Lysate Clarification 
 
To one litre pellet, 25 ml lysis buffer containing 1.5 ml of Lysozime (25mg/ml) and 1 
tablet of the Protease inhibitor Cocktail PIC (EDTA free Sigma) was added and the 
pellet resuspended. The pellet was homogenised with a Turax mixer and then incubated 
on ice for 15 min. The suspension was warmed up in a water bath at 37° C for 5 min 
before sonication. Cells were sonicated on ice for 3 min in continuous with amplitude of 
20%. Twenty-five ml of fresh lysis buffer was added and the 3 min sonication repeated 
as previously. Soluble protein was extracted by ultra-centrifugation for 50 min at 45000 
rpm in a Beckman L-70 ultracentrifuge, 50.2 Ti rotor. Cell debris was discarded and the 
supernatant filtered trough a Millipore filter.   
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18.4 Metal Affinity Chromatography 
 
18.4.1 Ni2+ affinity chromatography 
 
A 5 ml HisTrap FF crude column (GE Healthcare) Ni2+ affinity chromatography column 
was prepared for the purification of His-tagged proteins from 2 litres of culture. The 
column was washed with 10 column volumes (CV) of deionised water and then charged 
with nickel with 10 CV of NiSO4. The column was finally washed with 10 CV of 
deionised water and equilibrated with 10 CV of the required binding buffer until 
conductivity and UV absorbance at 280 nm reached a stable baseline. 
The clarified and filtered protein soluble extract was loaded onto the column at a flow 
rate of 5 ml/min and the flowtrough was collected to determine binding efficiency of the 
protein on a 15% SDS-PAGE gel. The FPLC apparatus (Bio-Rad) was programmed 
according to the following protocol (Table8): 
 
 
BB 
Buffer 
(%) 
EB 
Buffer 
(%) 
Imidazole 
concentration  
RunVolume 
(CV)  
Flowrate 
(ml/min) 
Fractionsize 
(ml) 
100 0 5mM 30 5 6 
95 5 50 mM 30 5 6 
85 15 150 mM 20 5 3 
70 30 300 mM 10 5 6 
0 100 1M 10 5 6 
 Table 8- Protocol for metal affinity chromatography (adapted for 2 litres of culture) 
 
The concentration of the protein was determined by the protein colorimetric Bradford 
assay (Bio-Rad). A volume corresponding to 1 µg of protein was loaded onto 12.5% 
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SDS-PAGE to determine the purity of the eluted protein for each elution fraction. The 
purified protein pool was dialyzed against the lysis buffer to eliminate imidazole and 
then concentrated. 
 
18.4.2 Co2+ affinity chromatography 
 
A 7.5 ml TALON Metal Affinity column was packed for the purification of His-tagged 
hCycH from 3 litres of culture. The column was washed with 10 column volumes (CV) 
of deionised water and then equilibrated with 10 CV of the required binding buffer until 
conductivity and UV absorbance at 280 nm reached a stable baseline. 
The clarified and filtered protein soluble extract was loaded onto the column at a flow 
rate of 5 ml/min and the flow trough was collected to determine binding efficiency of 
the protein on SDS-PAGE gel. The FPLC apparatus (Bio-Rad) was programmed 
according to the following protocol (Table9): 
 
 
BB 
Buffer 
(%) 
EB 
Buffer 
(%) 
Imidazole 
concentration  
RunVolume 
(CV)  
Flowrate 
(ml/min) 
Fractionsize 
(ml) 
99 1 10mM 30 5 6 
99-75 1-25 10-250 mM 12 5 3 
Table 9- Protocol for metal affinity chromatography (adapted for 3 litres of culture) 
 
The concentration of the protein was determined by the protein colorimetric Bradford 
assay. A volume corresponding to 1 µg of protein from each elution fraction was loaded 
onto a 12.5% SDS-PAGE to determine the purity of the eluted protein. The purified 
protein pool was dialyzed against the lysis buffer to eliminate imidazole and then 
concentrated according to experimental requirements.  
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18.4.3 GST-tag Fusion RAR  
 
Five ml Glutathione Agarose 4B resin was used for the purification of GST-tagged 
protein from 2 litres cultures. The resin was washed with 10 CV of deionised water and 
then equilibrated for 2 times with 50 ml binding buffer. After each washing step, the 
material was centrifuged for 2 min at 1000 rpm and the supernatant discarded. Clarified 
and filtered protein soluble extract was added to the resin and allowed to incubate for 60 
min at 4° C with slow and continuous mixing. The resin was recollected by 
centrifugation at 1000 rpm for 5 min, and the supernatant was collected to determine 
binding efficiency of the protein on SDS-PAGE gel. Roughly 5 ml supernatant was let 
on top of the resin, gently resuspended and transferred into an FPLC column. Ten ml 
lysis buffer was added to the column, the resin was allowed to settle and the column 
was sealed. The column was loaded onto a FPLC apparatus (Bio-Rad) and the non- 
specifically bound proteins were washed from the column with GST lysis buffer until 
UV absorbance at 280 nm reached a stable baseline. 
 
GST fusion enzymatic cleavage was carried out with on-column thrombin digestion. 
Glutathione Agarose 4B resin has a protein binding capacity of 8 mg/ml of resin. Sixty 
mg of pure protein could be purified with a 7.5 ml column. Considering the dead 
volume of tubes and other mechanic parts connected to the column, 8.5 ml lysis buffer 
containing 1.2 unit/ mg protein of Thrombin (1U/ µl) and 5 mM CaCl2 was prepared. 
The column was removed from the FPLC apparatus and the thrombin mixture slowly 
injected into the column. The column was sealed and incubated at 14° C for 30 hours. 
Elution of proteins cleaved from thrombin was carried out in 1 ml fractions on the 
FPLC apparatus with the lysis buffer, until the UV absorbance at 280 nm reached a 
stable baseline. The purified protein pool was concentrated up to the desired 
concentration. When GST fusion was not required the not pecifically bound proteins 
were washed from the column with lysis buffer, and the GST-fused protein was eluted 
with the lysis buffer, supplied with 10-mM glutathione solution and adjusted to the 
required pH.  
 
 
 105 
18.4.4 Size Exclusion Chromatography (Gel Filtration) 
 
The proteins were concentrated up to 4 mg/ml using a Centriprep centrifugal filtration 
device (10 KDa cutoff) and then centrifuged for 10 min at 14000 rpm. A maximum of 4 
ml per run of concentrated protein were injected onto the gel filtration column. 
   
Pharmacia HiLoad 16/60 Superdex 75 gel filtration column was equilibrated with 2 CV 
of gel filtration buffer. The concentrated protein was injected into a 5 ml loop and then 
automatically loaded on the column. The purification was carried out with 2 CV of gel 
filtration buffer at flow rate of 1 ml/min. The eluted protein was collected in 2 ml 
fractions. 
Aliquots corresponding to 1 µg of protein were loaded on 12.5% SDS-PAGE to 
determine the purity of the eluted protein fractions. The purified protein was 
concentrated to the required concentration using a Centriprep or Centricon centrifugal 
filtration device. 
 
18.5 Buffer exchange of RAR and RXR 
 
Buffer exchange was performed through dialysis using a membrane with 10 KDa cut off 
against the required buffer under constant stirring at 4° C.  Two changes of the dialysis 
buffer were carried out at 6 hours interval.  
Small volumes samples of concentrated protein were buffer exchanged using Illustra 
NAP-5 Columns filled with Sephadex G-25. The column was equilibrated with 10 ml 
buffer. A maximum volume of 500 µl of concentrated protein was added to the column. 
If the protein volume was less then 500 µl a required volume of buffer was added up to 
500 µl upon protein absorption into the column. The buffer exchanged protein was 
eluted with 1 ml buffer and collected in 3 x 300 µl fractions.     
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18.5.1 Buffers for : His-RARγS371E and RARγWT 
 
Lysis:  T20N500I5 (mM) pH8.0   
Binding: T20N500I5 (mM)  pH8.0             
     Elution: T20N500I1M (mM)  pH8.0             
     Gel filtration: T20N500Chaps2C12M0.15 TCEP1 (mM) pH 8.0 
 
18.5.2 Buffers for : GST-RARαS371E and RARαWT 
    
    Lysis: T20N5005I (mM) pH8.0 
Elution: T20N500Chaps2 TCEP1 (mM)  pH 8.0 
Gel filtration: T20N500Chaps1TCEP1 (mM)  pH 6.5 
 
18.5.3 Buffers for : His-PKA 
     Lysis: T20N5005I (mM) pH8.0 
     Elution: T20N500I1000 (mM)  pH8.0             
 
18.5.4 Buffers for : His-CycH 
Lysis: T50N500β2.5 (mM) pH8.0 
Binding: T50N500β2.5 (mM) pH8.0 
Elution : T20 mM N500β2.5 I1000 (mM)  pH8.0             
Gel filtration: T50N500β2.5 (mM) pH8.0 
 
Abbreviations: T= Tris HCl, N= NaCl, β= β−Mercaptoethanol, I= Imidazole, Chaps = 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate, TCEP= tris(2-carboxyethyl)phosphine, DTT= 
Dithiothreitol 
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18.5.5 Phosphorylation buffer for RARαWT 
 
Molar ratio (protein:PKA)=200:1 
[ATP]=2mM 
Buffer: T50N250(MgCl2)20 DTT1 (mM) pH 6.5 
  
      
18.6 SDS-PAGE Denaturing Gel Electrophoresis 
 
One dimension electrophoresis was performed on denaturing SDS-PAGEs to check 
protein purity. All the constituents found in the table 10 were mixed according to the 
desired concentration of acrylammide in the gel.  
The gel was cast, and the solution for the resolving gel loaded between the two gel 
plates. Water was loaded on top to avoid formation of air bubbles within the resolving 
gel. The stacking gel was added upon polymerisation of the stacking gel and combs 
containing the suitable number of wells were inserted between the gel plates. The 
protein samples were loaded and electrophoresis was carried out at 300 Volts for 40 
minutes.            
       
 
 
 
 
 
 
 
 
 
 
 Table 10- Composition of SDS PAGES at different concentrations. 
 10% 12% 15% 17% Stacking gel 
Water 6.1 ml 5.4 ml 4.1 ml 3.9 ml 3.8 ml 
Tris pH 8.8 3.15 ml 3.15 ml 3.15 ml 3.15 ml  
Tris pH 8.8     1.6 ml 
Acrylamide 40% 3.1 ml 3.9 ml 4.7 ml 5.3 ml 0.8 ml 
APS 10% 125 µl 125 µl 125 µl 125 µl 125 µl 
Temed 12 µl 12 µl 12 µl 12 µl 8 µl 
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19. Methods 
 
19.1 X-ray crystallography 
 
19.1.1 Basics 
 
The resolution limit (LR) of any optical method is defined by the equation: 
 
 Eq: 1                                                          LR = λ/2 
 
and is a function of the wavelength (λ) of the incident radiation47, 172. According to this 
equation common microscopes that use visible light (whose wavelength range between 
400 and 700 nm) cannot produce an image of individual atoms for which inter-atomic 
distances are only about 0.15 or 1.5Ǻ. 
X-rays are in the correct range to visualize atoms, and for this reason they are used to 
solve the atomic structures of proteins. However it is not possible to achieve a focused 
image of a single molecule for two reasons. 
First, the X-rays cannot be focused with lenses because they have refraction index close 
to one. This problem is overcome by crystallographers by measuring the position and 
intensities of the diffracted X-ray and then using a computer to simulate an image-
reconstructing lens. 
Secondly, a single molecule would scatter very weakly and the diffracted beams would 
be to week to be analysed. Using protein crystals provides a good solution to the 
problem. In a protein crystal single molecules display a high degree of order and are 
arranged in an identical orientation. Therefore, in a crystal, scattered waves can add up 
in phase producing strong X-ray beams.  
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A crystal behaves like a three-dimensional grate which diffracts the X-ray beam into 
discrete beams and gives rise to both constructive and destructive interference. Beams 
that interact constructively sum up and produce distinct spots on the detector, called 
reflections in the diffraction pattern. Each reflection contains information on all atoms 
in the molecule. 
 
W. L. Bragg showed that the beams scattered from a crystal can be treated as if they 
were originated by the reflection from equivalent and parallel planes of atoms in the 
crystal, each plane identified by the indices (h, k, l). According to Bragg’s description a 
set of parallel planes with indices (h, k, l) and interplanar spacing dhkl produces a 
diffracted beam when X-rays, of wavelength λ, enters and is reflected from the surface 
of the crystal with an angle θ that meets the condition: 
  
Eq:2                                                 2dhkl sinθ = nλ 
 
 
where n is an integer. Thus for two waves to be in phase with the wave which reflects 
from the surface, one wave have to travel a whole number of wavelengths while inside 
the crystal48.  For other angles of incidence θ’, for which Eq. 2 does not hold, waves 
reflected by successive planes are out of phase and thus interact destructively, reflecting 
no beam at that angle.    
 
The space constituted by the crystal reflections is in a reciprocal relationship to respect 
to the real space constituted by the crystal and is therefore called “reciprocal space”. 
Thus, the dimensions of the reciprocal space (Ǻ -1) are inversely proportional to 
dimensions of the real space (Ǻ).  
Each reflection in the reciprocal space the sum of electro-magnetic radiations and is 
therefore characterized by an amplitude and a phase. The calculation of the electronic 
density through Fourier transform requires the knowledge both of these parameters for 
each reflection147. Unfortunately, only information about amplitudes is accessible from 
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experimental measurements while no information is achievable about the phases. This is 
known as the “phase problem”.   
If the structure of the protein target displays sequence homology higher then 30% to 
that of a known protein the two structures are similar and the known protein can be used 
as a phasing model (molecular replacement).   
If no phasing model is available then the phases have to be obtained from alternative 
methods such as isomorphous replacement and anomalous scattering (MAD or SAD 
phasing). Both these methods use protein heavy atoms derivatives99, 167.  
In isomorphous replacement a heavy atom as mercury, lead or gold soaked into the 
crystal binds to specific sites on the protein. In most cases heavy atoms derivatives are 
isomorphic with crystals of the native protein and displaying same unit cell dimensions 
and symmetry and same protein conformation. Nevertheless the introduction of the 
heavy atoms originates reflections that are slightly different from that of the native 
crystal and can be used to obtain estimates of the phases.  
Anomalous scattering is based on heavy atoms ability to absorb X-ray at specific 
wavelengths. The X-ray wavelength is scanned past an absorption edge characteristic 
for each heavy atom, which changes the scattering in a known way167.  
Once the amplitudes and the phases are known, the electron density map is calculated 
by Fourier transform. With a good quality electronic density map manual construction 
of the three-dimensional model can be carried on basing on the knowledge of the 
protein sequence. The obtained model is then submitted to iterative cycles of structure 
refinement.  
 
19.1.2 Protein crystallization  
 
Crystal formation occurs in two stages including (1) nucleation and (2) growth. 
 
The phase diagram for crystallization (Fig.27) shows the solubility of a protein in 
solution as a function of the concentration of the precipitant and can be divided in four 
main zones6.  
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1) Precipitation zone. This region is characterized by a very high protein 
supersaturation. In this region the protein will precipitate. 
2) Metastable zone. This region is characterised by very low protein supersaturation. In 
this region very slow spontaneous nucleation can occur. 
3) Labile zone. This is the region of large supersaturation. Here spontaneous observable 
nucleation.  
4) Region of protein unsaturation. In this region the protein is completely dissolved and 
neither nucleation nor crystal grow can occur. 
 
 
 
 
Fig. 27- The phase diagram. 
The phase diagram in protein crystallization schematically represents how the protein and 
precipitant concentrations are related. The phase diagram is divided into 4 different zones. In the 
Unsaturated zone protein crystallization can not occur because the protein is completely 
solubilized. The Precipitation zone is highly saturated in protein concentration. In this region the 
protein will precipitate and would not form crystals. The Labile zone (or nucleation zone) is the 
region where crystal nucleation can occur. As the crystals start to form, the protein 
concentration decreases leading the system from the labile to Metastable zone, where crystal 
growth can occur. 
 
 
 
 112 
19.1.2.1 Nucleation  
 
Nucleation arises from a solution supersaturated with protein.  
Large supersaturation (labile zone) is required to overcome the activation barrier 
constituted by the free energy required to create microscopic clusters of proteins, the 
nuclei, from which the crystal will grow87.  Very low supersaturation (metastable zone) 
will require an unreasonable nucleation time whereas too much high supersaturation 
(precipitation zone) will lead to protein precipitation. 
Once nuclei have formed, the concentration of protein in the solute decreases leading 
the system to the metastable zone where crystal growth can occur. Persistence of 
nucleation conditions leads to the formation of many small crystals with poor 
diffracting quality36, 147. 
 
19.1.2.2 Growth 
 
Once nuclei have formed, the concentration of protein in the solute decreases leading 
the system to the metastable zone where crystal growth can occur. Persistence of 
nucleation conditions leads to the formation of many small crystals with poor 
diffracting quality36, 67, 147. Crystal growth requires different conditions than those of 
nucleation and it occurs in the metastable zone. Once a crystal has become larger than 
the initial nucleus, its growth becomes thermodynamically favoured, and the crystal can 
grow to macroscopic dimensions. Crystals grow by the attachment of molecules in 
layers to a growing surface and it occurs through protein supply either via diffusion or 
convection. 
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19.1.3 Parameters that influence Crystallization 
 
The difficulty of obtaining well diffracting macromolecular crystals is due to the fact 
that protein crystallization depends on a large number of different variables. These 
parameters include physico-chemical variables such as pH, temperature, precipitating 
agents and also macromolecular variables such as protein concentration, stability, and 
homogeneity. Therefore it is almost impossible to predict the condition in which the 
protein will crystallize48. Recently developed nanodrop crystallization robots and 
commercial available crystallization screenings allow screening of hundred of variables 
with a limited amount of conditions and provide crystallographers with precious help in 
the difficult task of finding the best conditions for protein crystallization. 
 
19.1.4 Crystallization Techniques 
 
Several methods are employed to crystallize proteins including batch, micro-batch35 and 
dialysis170. One widely used crystallization technique is vapour diffusion35. What 
follows is a brief introduction to the vapour diffusion method, the one that I used to 
crystallize RARγS371E. 
 
19.1.4.1 The Vapour Diffusion Method 
 
In the vapour diffusion method equilibrium is reached between two separated liquids. 
The protein drop is mixed with the crystallization buffer and suspended above a 
reservoir containing crystallization buffer. As the reservoir solution contains a higher 
precipitant concentration to respect to the protein drop, water slowly evaporates from 
the protein drop to achieve the same precipitant concentration as in the reservoir47. As 
water leaves the drop, the sample undergoes an increase in relative protein 
supersaturation. 
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The two main crystallisation techniques based on the vapour diffusion method are the 
sitting drop and the hanging drop. In the first one the protein drop sits in a concave 
depression on the top region of the rod placed in the sealed reservoir. In the hanging 
drop technique the protein drop is placed under a glass cover slip sealed on top of the 
reservoir.  
 
19.1.5 Crystals Cryo-protection. 
 
Crystals often suffer from radiation damage caused by X-rays.  X-ray radiation produce 
thermal vibration of the molecules, which create enough energy to break bonds between 
atoms. Further damages are caused by free active radicals, produced by X-ray damage 
of the polypeptide chain or production of H˙ or OH˙ from disruption of H2O molecules.  
Reducing the temperature to -196°C, would allow decrease of the thermal vibrations 
therefore limiting the extent of the radiation damage65, 66. In order to freeze the protein, 
chemicals known as cryo-protectants such as sucrose, MPD, PEGs, ethylene glycol land 
glycerol have to be added to the crystal. Cryoprotectant act disrupting the local order of 
water and reducing ice crystal formation65. In presence cryoprotectants water can be 
frozen rapidly and non diffracting vitreous ice is formed with no damage for the crystal. 
 
19.1.6 Nuclear Magnetic Resonance (NMR) 
 
NMR assesses the response of nuclear spins immersed in an intense and homogeneous 
magnetic field, to perturbations generated by the irradiation of sequence of radio pulses. 
The response to such pulse sequence is a sum of radio-frequencies emitted by the NMR 
active nuclei. 
The signal emitted by the nuclei decays exponentially with a characteristic time 
constant, called transverse relaxation time T2. Fourier-transformation converts the 
signal that is originally in the time domain into the frequency domain. The result of this 
transformation is a spectrum containing resonances lines representing the radio-
frequencies emitted by the nuclei.  
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The width of the resonance lines is inversely proportional to T2 which depends in turn 
on the molecular size of the molecule. Large molecules are characterized by fast 
relaxation rates (low values of T2) and determine therefore broad spectral lines 
representing the major limit of nuclear magnetic resonance spectroscopy. 
 
NMR studies leading to structure determination of macromolecules is based onto a 
process that entails the following steps: 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first task to accomplish is the preparation of highly purified protein samples. 
Inhomogeneous preparations may hinder spectra acquisition or severely affect the 
quality of the data. Optimization of the experimental conditions such as pH, ionic 
strength, and temperature is therefore essential step to ensure the quality of the NMR 
data. In an ideal case the protein in the sample must be stable at room temperature for 
several weeks. NMR samples range to 0.3 to 0.5 ml of protein in H20/D20 (90/10). 
Typical protein concentrations range from 0.5 to 2.0 mM. 
 
Preparation of protein solution 
sample 
NMR Spectroscopy 
Sequence Resonance Assignment 
Collection of conformational 
constraints 
Calculation of the 3D structure 
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NMR conventional one-dimensional spectra (1D) of biological macromolecules are far 
too complex for interpretation due to extensive signal overlapping. The invention of 
multidimensional spectra simplified one dimensional spectra by introducing additional 
spectral dimensions and therefore rendered accessible a lot extra information. 
 
Structural studies and three dimensional structure determination of small proteins with 
molecular weight below 10 kDa are usually performed through the combination of 2D 
homonuclear 1H NMR experiments such as [1H,1H]-TOCSY (Total Correlation 
Spectroscopy), and [1H,1H]-NOESY (Nuclear Overhauser Effect) and allows the 
sequential assignment of most proton signals to individual protons. TOCSY 
experiments provide correlation between different nuclei via a system of J coupling7, 182 
allowing through-bond correlations across the peptide bond in proteins isotopically 
enriched with 15N and 13C. NOESY experiments measure through-space correlations via 
the nuclear Overhauser effect (NOE) and provide correlations between pairs of 
hydrogen atoms which might be far apart in the protein sequence but are close in space, 
separated by a distance within 5 Å183.  
 .  
 
 
Proteins with a molecular weight higher then 10 KDa give rise to extensive signal 
overlapping. This prevents complete assignments of all 1H signals in proton spectra. In 
this case heteronuclear 2D experiments using 15N and 13C are usually performed.  In 
heteronuclear experiment the chemical shifts of 15N and 13C isotopes are used to spread 
the resonances. Besides being NMR active nuclei, 15N and 13C isotopes possess low 
natural abundance and a giromagnetic ratio which is considerably lower than that of 
protons. As a direct consequence, 15N and 13C display a remarkably lower sensibility 
than that of hydrogen. Two strategies are used to increase the sensitivity of these nuclei: 
(1) sample isotopic enrichment and (2) inverse NMR experiments in which the 
magnetization is transferred from proton to the heteronucleus, which results in the 
enhancement of the signal to noise ratio. A typical n-dimensional (nD) NMR 
experiment consists in the combination of (n-1) two-dimensional experiments which 
contains only one excitation and one detection period but repeats the evolution and 
mixing times (n-1) times. A typical nD NMR experiment thus follows the scheme:  
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excitation - (evolution - mixing)n–1 - detection 
 
During the excitation time the spins are perturbed and then let to precess freely during 
the evolution period (t1). In the mixing period (tm) the information on the chemical 
shift is transferred between correlated spins and only during the detection time the 
signal is physically recovered. Detection time (t2) is usually referred to as the “direct 
dimension” while the evolution times are often referred to as “indirect dimensions”. 
The proton offers the highest sensitivity to NMR to respect to the other active nuclei 
such as 15N and 13C. For this reason 1H constitutes the preferred nucleus for the 
detection of the NMR signal while the other nuclei are usually stimulated during 
evolution periods of multidimensional NMR experiments and their information is 
transferred to protons for detection. 
The most important inverse NMR experiments is the HSQC (heteronuclear single 
quantum correlation). Each signal in a HSQC spectrum represents a HN proton in the 
protein backbone bound to a nitrogen atom and therefore represents one single amino 
acid. A HSQC has no diagonal like the homonuclear spectrum because different nuclei 
are observed in the t1 and t2. An analogous experiment (13C HSQC) can be performed 
for 13C and 1H. 
 
 
Two-dimension spectra (2D) of proteins with a molecular weight higher than 30 kDa 
are often crowded with signals. In a 3D spectra the signals are spread out in a third 
dimension (usually 13C or 15N) by the combination of a TOCSY / NOESY with an 
HSQC experiment. 
The 3D triple resonance experiments exclusively correlate the resonances of the peptide 
backbone (HN(i), N(i), Cα(i), Hα(i), Cα(i-1), CO(i) and CO(i-1)). The 3D experiments 
used to identify the backbone resonances are, usually, HNCA or HNCACB, 
HN(CO)CA or HN(CO)CACB, HNCO, HN(CA)CO and HNHA. The HNCACB for 
example, correlates each H-15N group with both the intra- and the neighbouring inter-
residue Cα and Cβ. 
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As previously discussed, large molecules relax fast. This causes severe line broadening, 
poor spectral resolution and low signal to noise ratio.  
Great improvement of NMR spectra of biological macromolecules with molecular 
weights above 30 KDa has been achieved with deuterium labelling. Further 
improvement in the spectra resolution of such macromolecules is represented by the 
introduction of transverse relaxation-optimized spectroscopy (TROSY)133. TROSY uses 
constructive interference between different relaxation mechanisms and allows spectra 
acquisition for macromolecules with molecular weights above 100 KDa. 
 
 
. 
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Annex: 
 
 
 
hRARγ (LBD) (178-423): 
 
DSYELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLSIADQI
TLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDR
MDLEEPEKVDKLQEPLLEALRLYARRRRPSQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENPEMFE 
 
hRARγ S371E (LBD) (178-423) 
 
DSYELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLSIADQI
TLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDR
MDLEEPEKVDKLQEPLLEALRLYARRRRPEQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENPEMFE 
 
hRARα (LBD) (176-421) 
 
ESYTLTPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTVEFAKQLPGFTTLTIADQIT
LLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQD
LEQPDRVDMLQEPLLEALKVYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGLD 
 
hRARαS369E (LBD) (176-421) 
 
ESYTLTPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTVEFAKQLPGFTTLTIADQIT
LLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQD
LEQPDRVDMLQEPLLEALKVYVRKRRPERPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGLD 
 
hRXRα (LBD) (223-462) 
 
TSSANEDMPVERILEAELAVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAG
WNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSN
PAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT 
 
 
hCycH (1-323) 
 
MYHNSSQKRHWTFSSEEQLARLRADANRKFRCKAVANGKVLPNDPVFLEPHEEMTLCKYYEKRLLEFCSVFKPAMPRSV
VGTACMYFKRFYLNNSVMEYHPRIIMLTCAFLACKVDEFNVSSPQFVGNLRESPLGQEKALEQILEYELLLIQQLNFHLIVH
NPYRPFEGFLIDLKTRYPILENPEILRKTADDFLNRIALTDAYLLYTPSQIALTAILSSASRAGITMESYLSESLMLKENRTCLS
QLLDIMKSMRNLVKKYEPPRSEEVAVLKQKLERCHSAELALNVITKKRKGYEDDDYVSKKSKHEEEEWTDDDLVESL 
 
hPKA (2-351)  
 
GNAATAKKGSEVESVKEFLAKAKEDFLKKWENPTQNNAGLEDFERKKTLGTGSFGRVMLVKHKATEQYYAMKILDKQK
VVKLKQIEHTLNEKRILQAVNFPFLVRLEYAFKDNSNLYMVMEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHS
LDLIYRDLKPENLLIDHQGYIQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFF 
ADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVSDIKTHKWFATTDWIAIYQRKVEAPFIPKFRGS
GDTSNFDDYEEEDIRVSITEKCAKEFGEF 
 
        
Annex1. Sequences of hRARγ, hRARγ S371E, hRARα, hRARαS369E,hRXRα (LBDs),  
hCycH, hPKA. 
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Annex 2. Sequence alignement of LBDs of human RAR α, β, γ. The elements of the secondary 
structure are boxed (H for helices and S for β-strands). Amino-acid numbering is referred to 
RARγ.  
 
 
 
 
H1 H3 H4 H5 
S1 S2 H6 H7 H8 H9 H10 
H11 H12 
